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(57) ABSTRACT
The present invention provides methods to modify the
genetic regulation of mammalian tissue, bone, cells or any
combination thereof by preferential activation, up-regula-
tion and/or down-regulation. The method comprises steps of
tuning the predetermined profiles of one or more time-
varying stimulation fields by manipulating the B-Field mag-
nitude, rising slew rate, rise time, falling slew rate, fall time,
frequency, wavelength, and duty cycle, and exposing mam-
malian cells or tissues to one or more tuned time-varying
stimulation fields with predetermined profiles. Examples of
mammalian cells or tissues are chondrocytes, osteoblasts,
osteocytes, osteoclasts, nucleus pulposus, associated tissue,
or any combination. The resulted modification on gene
regulation of these cells, tissues or bones may promote the
retention, repair of and reduction of compromised mamma-
lian cartilage, bone, and associated tissue.
19 Claims, 8 Drawing Sheets
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GENETIC REGULATION OF BONE AND
CELLS BY ELECTROMAGNETIC
STIMULATION FIELDS AND USES
THEREOF
ORIGIN OF THE INVENTION
The invention described herein was made by employees
of the United States Government and may be manufactured
and used by or for the Government of the United States of
America for governmental purposes without the payment of
any royalties thereon or therefor.
BACKGROUND OF THE INVENTION
1. Field of the Innovation
The present innovation relates generally to the fields of
biophysics, bioelectromechanics, tissue regeneration, tissue
culture, and neurophysiology. More specifically, the present
innovation relates to the use of an electromagnetic field, and
preferably, a time-varying magnetic field, for modifying,
potentiating or controlling the growth and specific genetic
expression of biological cells and tissue, such as mammalian
tissue. More specifically, the present innovation relates to
the use of a noninvasive method and apparatus comprising
relatively low frequency magnetic fields for modifying the
genetic regulation of mammalian chondrocytes, osteoblasts,
osteocytes, osteoclasts, nucleus pulposus, associated tissue,
or any combination.
2. Background and Related Art
Cartilage is a type of dense connective tissue existing
within many joints and is composed of specialized cells
called chondrocytes that produce a large amount of extra-
cellular or cartilaginous matrix comprised of actin and
collagen fibers, proteoglycans, glycosaminoglycans, and
elastin fibers. Chondrocytes are the only cells found in
cartilage.
Unlike other connective tissues, cartilage does not contain
blood vessels or is referred to as avascular. Thus, compared
to other connective tissues, cartilage grows and repairs more
slowly.
There are several diseases which can affect the cartilage.
Chondrodystrophies are a group of diseases characterized by
disturbance of growth and subsequent ossification of carti-
lage. Osteoarthritis (OA) is a common disease affecting
cartilage.
Cartilage has limited repair capabilities, because chon-
drocytes are bound in lacunae, they cannot migrate to
damaged areas. Therefore, if damaged, cartilage is difficult
to heal. Also, because hyaline cartilage does not have a
blood supply, the deposition of new cartilaginous matrix is
slow.
Acetaminophen/paracetamol is generally used as a first
line treatment and anti-inflammatory drugs (NSAIDs) are
only recommended as add on therapy if pain relief is not
sufficient. There is a need to find definitive answers and to
develop procedures that relieve arthritis symptoms and
produce a durable replacement for damaged cartilage.
Bones are rigid organs that form part of the endoskeleton
of vertebrates. One of the types of tissue that makes up bone
is the mineralized osseous tissue, also called bone tissue,
which gives it rigidity and a honeycomb-like three-dimen-
sional internal structure.
There are several types of cells constituting the bone. For
example, osteoblasts are mononucleate bone-forming cells
that descend from osteoprogenitor cells. They are located on
the surface of osteoid seams and make a protein mixture
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known as osteoid, which mineralizes to become bone.
Osteoid is primarily composed of Type I collagen.
In the disease commonly known as osteoporosis, bone
demineralizes and becomes abnormally rarefied. Dimin-
5 ished bone density may lead to vertebrae collapse, fractures
of hips, lower arms, wrists, ankles as well as incapacitating
pains.
Current therapies comprise invasive procedures (e.g. sur-
gery or drug administration) as opposed to the described
io innovation which is a non-invasive procedure. Alternative
nonsurgical therapies for such diseases include electrical
bone growth stimulation comprised of electric and magnetic
field therapies. However these therapies are moderately
invasive as they rely on either skin contact or insertion of
15 probes/electrodes into the tissues.
Nucleus pulposus is the jelly-like substance in the middle
of the spinal disc that functions to distribute hydraulic
pressure in all directions within each disc under compressive
loads. The nucleus pulposus comprises disc chondrocytes
20 (as opposed to articular chondrocytes), collagen fibrils, and
proteoglycan aggrecans that have hyaluronic long chains
which attract water. Attached to each hyaluronic chain are
side chains of chondroitin sulfate and keratan sulfate.
Electric and Magnetic Fields
25 An electric field is a property that describes the space that
surrounds electrically charged particles. Electric fields are
created by differences in electric potential or voltage: i.e.,
the higher the voltage, the stronger will be the resultant
electric field. In contrast, magnetic fields that are generated
30 electromagnetically are created when electric current flows:
i.e., the greater the current, the stronger the magnetic field.
An electric field will exist even when there is no current
flowing. In contrast, a magnetic field generated electromag-
netically will not exist when there is no current. If current
35 does flow, the strength of the magnetic field that is generated
electromagnetically will vary with power consumption but
the electric field strength will be constant. Resultant forces
are related to both electric and magnetic fields. The force
associated with an electric field depends on a stationary or
40 static charge. Conversely, the force exerted on a charged
particle associated with a magnetic field (i.e., Lorentz force)
depends on a moving charge. Further, electric and magnetic
fields are not entirely mutually exclusive. For example,
charged particles do not only produce electric fields. As
45 charges move, they generate magnetic fields, and if the
magnetic field changes, the change in said magnetic field
will generate electric fields. Thus weak metals (ions) such as
CA2+, K+, Li+, and Mgt+ are all subject to modulation or
resonance effect and can be made to move sub-cellularly due
50 to magnetic flux. Stated differently, a changing magnetic
field gives rise to an electric field. In nature lightning is an
example of an atmospheric electrical discharge that creates
an attendant magnetic field.
Electrical Stimulation Therapies
55 Electrical stimulation therapies include: capacitive cou-
pling (CC); and direct current (DC) or direct coupling. The
original basis for forms of electric stimulation therapy was
the observation that physical stress on bone causes the
appearance of tiny electric currents (i.e., a piezo-electric
60 effect) that, along with mechanical strain, were thought to be
the mechanisms underlying transduction of the physical
stresses (compression and tension) into an electrical signal
that promotes bone formation. CC relies on an electric field
that is generally generated by 2 capacitive plates or elec-
65 trodes placed on a patient's skin on opposite ends of a region
of interest to apply electrical stimulation in the region of
interest. DC-based therapies require the placement of oppos-
US 9,896,681 B2
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ing electrodes in direct contact with the skin surface sur-
rounding the tissue of interest (Trock, 2000) and generally
involve implantation of the electrodes. The region of interest
is stimulated by a constant direct current.
Magnetic Field Therapies 5
Magnetic field therapies include: time-varying magnetic
field (TVMF) therapies including pulsed electromagnetic
field (PEMF) therapies. The general use of time-varying
magnetic fields to stimulate the growth of cells has been
disclosed in the related art. It has been theorized that the i0
piezo-electric properties in human tissue such as bone and
cartilage forms the basis for regulating bone and cartilage
formation. Specifically, because a magnetic field imposes a
force on magnetic particles and moving electrically charged 15
particles, the magnetic field forces simulate physical stress
in human tissue thereby resulting in small, induced currents
(Faraday currents) in the tissue's highly conductive extra-
cellular fluid. In general, time-varying magnetic field thera-
pies involve the use of coils to electrically generate a 20
magnetic field. PEMFs are considered a subset of time-
varying magnetic field therapies and are generally associated
with pulses or bursts in its waveforms. Resultant waveforms
used in PEMF therapies can be substantially monophasic,
substantially biphasic, substantially square, sinusoidal, or 25
substantially triangular. Further, PEMF therapies are gener-
ally comprised of frequencies on the lower end of the
electromagnetic spectrum such as from 6-500 Hz. Further,
waveforms used in PEMF therapies generally have high
rising and falling slew rates on the order of Tesla/sec, 30
thereby promoting said pulses or bursts.
In U.S. Pat. No. 7,179,217 an apparatus for enhancing
tissue repair in mammals is disclosed. The disclosed appa-
ratus comprises: a sleeve for encircling a portion of a
mammalian body part, said sleeve comprising an electrically 35
conductive coil capable of generating a magnetic field when
an electrical current is applied thereto, means for supporting
the sleeve on the mammalian body part; and a means for
supplying the electrically conductive coil with a square
wave time-varying electrical current sufficient to create a 40
time-varying magnetic force of from approximately 0.05 G
to 0.5 G within the interior of the coil in order that when the
sleeve is placed on a mammalian body part and the time-
varying magnetic force of from approximately 0.05 G to 0.5
G is generated on the mammalian body part for an extended 45
period of time, tissue regeneration within the mammalian
body part is increased to a rate in excess of the normal tissue
regeneration rate that would occur without application of the
time-varying magnetic force. The electrically conductive
coil is preferably a ferromagnetic material, such as wire, 50
with approximately ten windings per inch. The sleeve can be
placed on a body part, e.g. an arm or a leg, of the mammal
and the body part exposed to the 0.05 G to 0.5 G time-
varying magnetic force for an extended period of time to
enhance tissue repair, such increasing the healing rate of 55
bone fracture repair or increased healing rate of ulcerated
skin. It is preferable that the treated mammal is provided an
increased level of calcium ions (Ca+ or Ca++) during the
application of the time-varying magnetic force.
Anabolic and Catabolic Gene Expressions 60
In recent decades, many more hormones with at least
some effects have been discovered, including cytokines or
paracrine and autocrine factors which are the products of
genomic up or down regulations. Further specific genes and
some molecules work in concert with each other or in gene 65
cascades (chaperones) which facilitate the end goal of tissue
remodeling, with processes such as glucose metabolism
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fluctuating to match an animal's normal periods of activity
throughout the day (Ramsey, et al., 2007).
Similarly, known biomolecules such as vitamins are use-
ful in perpetuating the process of normal cartilage and bone
maintenance. Vitamin D (specifically D3) and Vitamin K are
known to a degree in relation to normal mammalian (spe-
cifically human) physiology (Atkins, 2009), (Koshihara,
1997). The inventors postulate that due to the facilitated
stimulation of important gene expressions (specifically
osteocalcin up-regulation which was unanticipated as part of
the responding cascade) that addition of increased concen-
trations of these two vitamins during treatment of the
affected area (ROI) in any outlined regime or matrix will
further enhance and accelerate the formation of new bone
and differentiate the expression of bone from cartilage in the
subject tissue as mineralization will produce bone and not
cartilage.
Anabolism is the set of metabolic pathways or genomic
and protein responses that construct molecules from smaller
units (de Bolster, 1997). These reactions require an energy
system which in the case of cells is derived from other
genomic responses in the breakdown of energy "packets" in
the cell. One way of categorizing metabolic processes,
whether at the cellular, organ or organism level is as anabolic
or as catabolic, which is the opposite of anabolic.
Catabolism is the set of pathways that break down mol-
ecules into smaller units and release energy (de Bolster,
1997). In catabolism, large molecules such as nucleic acids,
proteins, polysaccharides, and lipids, and are broken down
into smaller units such as amino acids, nucleotides, mono-
saccharides, and fatty acids, respectively. For the purposes
herein, "catabolic" will be associated with a reparative
function and specifically, the breakdown, reorganization, or
the degeneration of tissue from an organic perspective.
Currently, full advantage is not being taken of the use of
these biophysical and electrical stimuli. However, as the
underlying mechanisms at the molecular and cellular level
become understood, medical instrumentation using this
medical technology will become more widely implemented.
Currently, the related art primarily depends on frequency
and B-Field magnitude associated with an electromagnetic
field waveform for the stimulated growth of biological cells
and associated tissue. In fact, related art publications indi-
cate that a B-Field magnitude is the primary control variable
for affecting biological cell and tissue growth. At some
point, the B-field magnitude's effect becomes more of a
thermal effect as compared to a physical force imparted at
the cellular level. For example any magnetic field greater
than 30 kHz falls into the radio frequency range and is
known to result in thermal heating effects at the sub-cellular
level. The related art is deficient in discovery of a specific
stimulation field profile necessary for up-regulating and
down-regulating specific genes, wherein said profile is com-
prised of not only frequency and B-Field magnitude, but also
waveform shape, rise time, rising slew rate, fall time, falling
slew rate, duty cycle, dwell time, time of exposure, and other
possible factors. The therapeutic implications of the discov-
ery of specific profiles associated with stimulating specific
genes will be explained herein. Thus, it would be desirable
to provide an apparatus and method of use which would
promote the stimulation of specific genes by a specific
stimulation field of predetermined profile.
SUMMARY OF THE INVENTION
The present invention relates to a system and method to
modifying the genetic regulation of mammalian chondro-
US 9,896,681 B2
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cytes, osteoblasts, osteocytes, osteoclasts, nucleus pulposus,
associated tissue, or any combination. There are multiple
embodiments with respect to what comprises "associated
tissue". For example, associated tissue may comprise carti-
laginous tissue, osseous tissue, connective tissue, cancellous
tissue, tendon and muscle, or any combination, etc. More
specifically, the act of modifying may be comprised of
promoting the retention, repair of and reduction of compro-
mised cartilage, bone, and associated tissue in a mammalian
system by preferential stimulation of the aforementioned
cell types in the mammalian physiology in a specific order
or sequence. A stimulation field generator may be used to
deliver a tuned time-varying stimulation field profile of
predetermined performance characteristics or Figures of
Merit (FOM) to the targeted tissue for a predetermined tuned
exposure time or plurality of tuned exposure time sequences
wherein said FOMs may comprise B-Field magnitude, fre-
quency, wavelength, rising slew rate, falling slew rate, rise
time, fall time, and duty cycle(s). The apparatus may include
several components comprising: 1) a power source, 2)
control component, and 3) a transmission component. The
power source supplies the electricity necessary to produce
an electromagnetically generated time-varying stimulation
field of predetermined profile that is controlled and governed
by the control component of the apparatus wherein said
time-varying stimulation field is induced to a target tissue or
region of interest (ROI) by a transmission component. The
transmission component may take the embodiment of stan-
dard transmission antennae, magnetic coils, a complexed
array that consists of multiple coils, antennae to deliver the
correct magnetic field to the ROI in the proper field density,
or any combination. In an embodiment, the apparatus deliv-
ers a tuned time-varying stimulation field comprising at least
one tuned predetermined profile to preferentially stimulate
(up-regulate, down-regulate, or a combination of both) the
biochemical cellular and sub-cellular molecular responses to
trigger the activation of known mammalian genes respon-
sible for the regeneration, restoration, repair, maintenance,
or any combination of cartilage, bone, or both.
It is an object of the present invention to provide an
apparatus for biomedical therapeutic applications based on
the application of time-varying magnetic fields, and more
particularly to TVMFs produced in a device which utilizes
a tuned electrical signal capable producing a tuned prede-
termined time-varying stimulation field comprised of at least
one tuned predetermined profile at a treatment site for
cartilage, bone, and soft tissue therapy.
It is another object of the present invention to provide a
multi-functional, modular device using wire coils that create
a tuned predetermined time-varying stimulation field of at
least one tuned predetermined profile designed for penetra-
tion into cartilage, bone, associated tissue, or any combina-
tion for the treatment of osteoarthritis, fractures, osteoporo-
sis, and the like.
It is a further object of the invention to provide at least one
tuned electrical signal based on frequency, amplitude, rise
time, rising slew rate, fall time, falling slew rate, duty cycle,
dwell cycle(s), or any combination to a stimulation field
generator apparatus in order to generate and emit a tuned
time-varying stimulation field of at least one tuned prede-
termined profile to modify the genetic regulation of the
aforementioned mammalian cells.
It is yet another object of the invention to provide time-
varying magnetic field neuromuscular stimulation utilizing a
predetermined time-varying stimulation field for reducing
muscle atrophy as a countermeasure to body unloading
6
effects. These effects may be encountered in a hospital while
bead ridden or in another type of environmental challenge
such as human spaceflight.
In an embodiment, the apparatus may emit and deliver to
5 the target area or tissue a substantially square wave between
about 9 Hz to about 200 Hz; with a rise time between about
125 µs to about 1 ms; a rising slew rate of between about 2.0
kG/s to about 50.0 kG/s; a fall time between about 125 µs to
1 ms; a falling slew rate of between about 2.0 kG/s to about
io 500.0 kG/s, or any combination. Additionally, the apparatus
may operate on a duty cycle of between about 65% to about
80% (and a subsequent dwell time of between about 35% to
about 20%, respectively). Still further, the apparatus may
operate for a predetermined tuned exposure time from about
15 1 hour to about 1200 hours in a continuous manner or based
on a predetermined time schedule. Deviations from these
FOMs may elicit deferential responses with regard to mam-
malian cells, ion transport, and thus genetic and protein
expression.
20 In an embodiment, the innovation is a method comprising
the steps of positioning an apparatus in a predetermined
proximate spatial relationship to a region of interest com-
prising damaged chondrocytes, osteoblasts, osteocytes,
osteoclasts, nucleus pulposus, or any combination, wherein
25 said apparatus is capable of producing a time-varying stimu-
lation field; generating a predetermined time-varying stimu-
lation field in the form of a substantially square waveform
with a B-Field magnitude from about 0.6 G to about 50 G,
a frequency from about 9 Hz to about 200 Hz, a rise time of
30 from about 0.75 ms to about 1 ms, rising slew rate from
about 2.0 kG/s to about 20.0 kG/s, a fall time from about 125
µs to about 300 µs, a falling slew rate from about 5.0 kG/s
to about 50.0 kG/s, and a duty cycle from about 65% to
about 80%, and wherein said stimulation field promotes the
35 growth of chondrocytes, osteoblasts, osteocytes, osteoclasts,
nucleus pulposus, or any combination.
In an embodiment, the innovation is a method comprising
the steps of providing an apparatus comprising a power
source, control component, and a transmission component;
40 positioning a region of interest comprising damaged chron-
drocytes, osteoblasts, osteocytes, osteoclasts, nucleus pul-
posus, or any combination in proximate spatial relationship
to said apparatus; operating said apparatus to generate
time-varying stimulation filed comprised of a substantially
45 square wave with a frequency from about 9 Hz to about 200
Hz, a rise time of from about 0.75 ms to about 1 ms, rising
slew rate from about 2.0 kG/s to about 20.0 kG/s, a fall time
from about 125 µs to about 300 µs, and a falling slew rate
from about 5.0 kG/s to about 50.0 kG/s, wherein the duty
50 cycle of said square wave is from about 65% to about 80%,
wherein the operation of said apparatus produces said time-
varying stimulation field, and wherein the stimulation field
promotes the growth of chondrocytes, osteoblasts, osteo-
cytes, osteoclasts, nucleus pulposus, or any combination.
55 With particular reference to FIG. 6, in another embodiment,
power source, control component, transmission component,
or any combination is incorporated in a sleeve 20 (such as
for example, described in U.S. Pat. No. 7,179,217, wherein
the power source, control component, and transmission
60 component are operably connected to each other. The sleeve
is capable of wrapping around a ROI 21, such as a body part
or an appendage of a mammalian physiology and is capable
of delivering a magnetic field 34 to said ROI.
In an embodiment, a pulsed stimulation field of predeter-
65 mined profile may be used in combination with (either
serially or in parallel) a time-varying stimulation field of
predetermined profile for determining differential matrix
US 9,896,681 B2
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signaling for accomplishing various therapeutic applica-
tions. In another embodiment, the control component con-
trols predetermined characteristics of one or more fields. In
another embodiment, the control component is comprised of
a conductor, an amplifier, or both.
In an embodiment, the stimulation field is comprised of a
magnetic field of a predetermined profile capable of accom-
plishing CA2+ ionic transport modulation for mammalian
chondrocytes, osteoblasts, osteocytes, osteoclasts, nucleus
pulposus, associated tissues, or any combination. In another
embodiment, the stimulation field is comprised of a mag-
netic field of a predetermined profile capable of modifying
the genetic regulation of mammalian chondrocytes, osteo-
blasts, osteocytes, osteoclasts, nucleus pulposus, associated
tissue, or any combination. In still another embodiment, the
stimulation field is capable of producing or suppressing
specific biomolecules that are associated with and necessary
and responsible for the growth, retention, regeneration and
repair of chondrocytes, osteoblasts, osteoclasts, osteocytes,
and nucleus pulposus.
In an embodiment, the predetermined time-varying simu-
lation field is capable of modifying the genetic regulation of
mammalian chondrocytes, osteoblasts, osteocytes, osteo-
clasts, nucleus pulposus, associated tissues, or any combi-
nation to increase the growth rate of these cells and tissues
greater than the normal physiological rates of growth. In
another embodiment, the predetermined time-varying stimu-
lation field is capable of being regulated to enhance the
growth, retention, restoration, and repair of cells associated
with activating gene families including, but not limited to:
BMP, actin, thrombospondins, lamanins, proteoglycans, col-
lagens, tumor necrosis factors, transforming growth factors,
and cytoskeletal families.
As used in this paper, a "stimulation field" refers to a
magnetic field generated electromagnetically wherein the
magnetic field is comprised of a B-Field wherein a particle
having an electric charge, q, and moving in said B-field with
a velocity, v, experiences a physical force. Further, as used
in this paper, a "region of interest" is defined as an area
targeted to be exposed to a stimulation field. A region of
interest can be, for example; a rotating wall vessel contain-
ing biological materials or a predetermined area on a
patient's body. Still further, as used in paper, a "profile"
refers to a waveform. In addition, "figures of merit" refer to
measurable performance characteristics or values. Still fur-
ther, "anabolic" refers to the building of tissue or the
regeneration of tissue from an organic perspective. "Cata-
bolic" refers to a reparative function and specifically, the
breakdown, reorganization, or the degeneration of tissue
from an organic perspective. HCH as used herein refers to
human chondrocytes. HOB as used herein refers to human
osteoblasts. As used herein, NDR refers to no or zero
differential regulation. As used herein, NRE refers to no
regulated effect. As used herein in the claim(s), when used
in conjunction with the word "comprising", the words "a" or
"an" mean one or more.
BRIEF DESCRIPTION OF THE DRAWINGS
So that the matter in which the above-recited features,
advantages and objects of the invention, as well as others
that will become clear, are attained and can be understood in
detail, more particular descriptions of the invention briefly
summarized above may be had by reference to certain
embodiments thereof that are illustrated in the appended
drawings. These drawings form a part of the specification.
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The appended drawings illustrate preferred embodiments of
the invention and therefore are not to be considered limiting
in their scope.
FIG. 1 depicts an exemplary stimulation field profile of a
5 substantially biphasic, square waveform.
FIG. 2 depicts an exemplary stimulation field profile of a
substantially monophasic, delta waveform.
FIG. 3 illustrates an exemplary stimulation field generator
apparatus.
to FIG. 4 illustrates an exemplary rotating wall vessel.
FIG. 5 illustrates an exemplary rotating wall vessel inte-
grated with an exemplary stimulation field generator appa-
ratus.
FIG. 6 illustrates an exemplary stimulation field generator
15 apparatus in the form of a sleeve wherein said stimulation
field generator apparatus delivers a magnetic field of pre-
determined profile to a region of interest on a mammalian
physiology.
FIG. 7 depicts a flowchart of a method to modify the
20 genetic regulation of mammalian tissue, bone, or any com-
bination comprising the steps of: exposing said mammalian
chondrocytes, osteoblasts, osteocytes, osteoclasts, nucleus
pulposus, associated tissue, or any combination to at least
one tuned time-varying stimulation field.
25 FIG. 8 depicts a flowchart of sub-steps associated with a
step of exposing mammalian chondrocytes, osteoblasts,
osteocytes, osteoclasts, nucleus pulposus, associated tissue,
or any combination to at least one tuned time-varying
stimulation field.
30 FIG. 9 depicts a flowchart of sub-steps associated with a
step of tuning at least one tuned predetermined profile for at
least one tuned time-varying stimulation field.
FIG. 10 depicts a flowchart of sub-steps associated with
a step of analyzing genetic anabolic and catabolic effects
35 from the results of at least one gene expression analyses.
FIG. 11 depicts a flowchart of sub-steps associated with a
step of generating at least one conclusion from a step of
analyzing.
40 DETAILED DESCRIPTION OF THE
INVENTION
The innovation utilizes stimulation fields of at least one
predetermined profile to modify the genetic regulation of
45 mammalian chondrocytes, osteoblasts, osteocytes, osteo-
clasts, nucleus pulposus, associated tissues, or any combi-
nation. In an embodiment, the at least one predetermined
profile is tuned in accordance with empirical techniques.
Various embodiments of the apparatus and method are
5o applicable but are not limited to the diseases of osteoarthritis
and osteoporosis as well as to be used to treat and resolve
damaged structures of the skeletal and soft or connective
tissues of the physiology. The innovation described herein
uses a completely non-invasive method and protocol to
55 affect the desired results outlined above. The innovation also
relates to a method of treating diseased tissue in a human
through the exposure of a tuned or tunable stimulation field
of at least one tuned predetermined profile to diseased tissue
in a human, including osteoarthritis, osteoporosis, osteope-
6o nia, and other cartilage/bone diseases, defects, and injuries.
In an embodiment, the method includes steps associated
with tuning or selecting a tuned predetermined time-varying
stimulation field of at least one tuned predetermined profile
for at least one predetermined time period wherein different
65 profiles may be employed for different periods of time. It is
well known that an electrical current flowing through a wire
generates a magnetic field. The resultant magnetic field is
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produced by the motion of electrical charges, i.e., electrical
current. However, the specific manner of tuning electrical
signal characteristics or FOMs and to produce a tuned
predetermined time-varying stimulation field to optimize the
re-growth of tissue based on cellular and sub-cellular obser-
vations is not well-known in the related art. The innovation
described herein attempts to solve at least some of the
problems described above.
In an embodiment, the innovation is comprised of a
device that can be wrapped around a ROI such as, for
example, joints where damaged cartilage is located. The
device may produce at least one stimulation field at a
pre-determined frequency, wavelength, magnitude, rise
time, rising slew rate, fall time, falling slew rate, duty cycle,
or any combination that will result in tissue modification.
For example, this embodiment addresses problems associ-
ated with invasive surgical techniques by non-invasively
applying a TVMF to the affected areas to regenerate and
re-grow cartilage cells, bone cells, or both.
As an example in an embodiment, the inventors have
determined that successful reproducible transmission of
electrically generated stimulation fields of predetermined
frequency are comprised of five factors: (1) the profile or
waveform of the stimulation field comprising predetermined
FOMs; (2) a sufficient field flux to overcome the ambient
environment; (3) design of a transmission component (an-
tennae); (4) change of slew rate and rise and fall time; and
(5) exposure time of the ROI to the stimulation field. The
innovation described herein results from laboratory studies
at the cellular level designed to elucidate the fundamental
underlying mechanisms that link stimulation field exposure
to biological effects. Specifically, the results of the inven-
tors' research identify mechanisms based on molecular or
cellular changes that are brought about by stimulation fields
of predetermined profile thereby providing clues as to how
a physical force is converted or transduced into a biological
action within a mammalian physiology.
With particular reference to FIG. 7, for example, in an
embodiment, the innovation comprises a method to modify
the genetic regulation of mammalian tissue, bone, or any
combination comprising the steps of: exposing said mam-
malian chondrocytes, osteoblasts, osteocytes, osteoclasts,
nucleus pulposus, associated tissue, or any combination to at
least one tuned time-varying stimulation field 11 comprised
of at least one tuned predetermined profile for a predeter-
mined tuned exposure time or plurality of tuned exposure
time sequences wherein said at least one tuned predeter-
mined profile is comprised of a plurality of tuned predeter-
mined figures of merit and is controllable through at least
one of said plurality of tuned predetermined figures of merit,
wherein said plurality of predetermined tuned figures of
merit is comprised of a tuned B-Field magnitude, tuned
rising slew rate, tuned rise time, tuned falling slew rate,
tuned fall time, tuned frequency, tuned wavelength, and
tuned duty cycle; controlling said at least one tuned time-
varying stimulation field to produce said at least one tuned
predetermined profile 12 by manipulating said tuned B-Field
magnitude, said tuned exposure time or said plurality of
tuned exposure time sequences and at least one of the
following said tuned predetermined figures of merit: said
tuned rising slew rate, said tuned rise time, said tuned falling
slew rate, said tuned fall rime, said tuned frequency, said
tuned wavelength, or said tuned duty cycle. The method may
be further comprised of the step of tuning said at least one
predetermined profile 50 associated with at least one time-
varying stimulation field thereby resulting in at least one
tuned time-varying stimulation field comprised of at least
10
one tuned predetermined profile, wherein said at least one
tuned predetermined profile is comprised of a plurality of
tuned predetermined figures of merit and is controllable
through at least one of said plurality of tuned predetermined
5 figures of merit, wherein said plurality of predetermined
tuned figures of merit is comprised of a tuned B-Field
magnitude, tuned rising slew rate, tuned rise time, tuned
falling slew rate, tuned fall time, tuned frequency, tuned
wavelength, and tuned duty cycle.
to With particular reference to FIG. 8, for example, in an
embodiment, the step of exposing said mammalian chon-
drocytes, osteoblasts, osteocytes, osteoclasts, nucleus pul-
posus, associated tissue, or any combination to at least one
15 tuned time-varying stimulation field 11 may be comprised
of: providing a stimulation field generator apparatus in
proximate spatial relationship to said mammalian chondro-
cytes, osteoblasts, osteocytes, osteoclasts, nucleus pulposus,
associated tissue, or any combination 18; and generating
20 said tuned time-varying stimulation field using said stimu-
lation field generator apparatus 19.
With particular reference to FIG. 9, for example, in an
embodiment, the step of tuning may be comprised of:
providing at least one set of cellular samples in at least one
25 rotating wall vessel 51; exposing said at least one set of
cellular samples 52 to at least one experimental time-varying
stimulation field comprising at least one experimental pre-
determined profile; conducting at least one gene expression
analyses to said at least one set of cellular samples 53;
3o analyzing the genetic anabolic and catabolic effects from the
results of said at least one gene expression analyses 54;
generating at least one conclusion from said step of analyz-
ing 55; adjusting said at least one experimental predeter-
mined profile based on said at least one conclusion 56; and
35 selecting at least one tuned time-varying stimulation field
comprised of at least one tuned predetermined profile for a
predetermined tuned exposure time or a plurality of tuned
exposure time sequences 57. In an embodiment, the step of
conducting at least one gene expression 53 may occur after
40 said step of exposing said at least one set of cellular samples
52. In an embodiment, the step of adjusting said at least one
experimental predetermined profile 56 may occur if said at
least one conclusion does not meet predetermined criteria.
The at least one set of cellular samples may be selected from
45 the group consisting of human chondrocytes and human
osteoblasts in addition to associated tissues.
With particular reference to FIG. 10, for example, in an
embodiment, the step of analyzing the genetic anabolic and
catabolic effects 54 may be comprised of: selecting a pre-
5o determined set of genes or gene families 58; calculating a
fold change for each gene in said set of genes from the
results of said at least one gene expression 59; determining
if each of said fold change is consistent with up-regulation
or down-regulation for said each gene 60; and classifying
55 each of said fold change as an anabolic or catabolic effect
based on said up-regulation or down-regulation for said each
gene 61.
With particular reference to FIG. 11, for example, in an
embodiment, the said step of generating at least one con-
60 clusion 55 may be comprised of: establishing a relative
value for each of said anabolic or catabolic effect on said
up-regulation or down-regulation for said each gene 62;
comparing each of said relative value in combination 63;
selecting a conclusion comprised of either a substantive net
65 anabolic effect, a substantive net catabolic effect, a net
anabolic effect, a net catabolic effect, or no determinative
effect 64.
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In an embodiment, a substantially square wave signal
with a frequency from about 10 Hz to about 200 Hz can be
induced to a ROI via a transmission component with the
intent of influencing and thereby modifying the sub-cellular
molecular components of mammalian chondrocytes, osteo-
blasts, osteocytes, osteoclasts, nucleus pulposus, (and asso-
ciated tissue) thereby affecting the genomic and proteomic
output or expression of these cells. The expression deltas are
directly responsible, as compared to controls (untreated
cells), for signaling differences at the sub-cellular and
nuclear levels of the cells. The inventors have determined
through laboratory tests that various embodiments of a
stimulation field with a predetermined profile via manipu-
lation of an electrical signal's FOMs, with specific ranges of
electrical signal characteristics used to generate a stimula-
tion field of predetermined profile, result in modification of
cartilage and bone cells. For example, a time-varying stimu-
lation field of predetermined profile comprised of a particu-
lar B-Field magnitude, frequency, rise time, fall time, slew
rate, and wavelength for a predetermined exposure time or
plurality of exposure time sequences (i.e., an exposure time
schedule) may be used to preferentially excite specific
sub-cellular organelles within the subject cells resulting in
the desired events previously enumerated. The resultant
profile may be a substantially square waveform.
Laboratory tests were comprised of exposing separate
ROIs to a time-varying stimulation field of predetermined
profile and a PEMF of predetermined profile wherein the
ROIs was comprised of a rotating wall vessel (RWV). The
RWV was inserted into a transmission component (see FIG.
5). The RWV contained a predetermined volume of micro-
carriers and predetermined cell volume comprised of human
chondrocytes or human osteoblasts; and cell growth media.
Both 2D and 3D culturing techniques were employed. Cell
growth observations and analysis were then performed.
Stimulation Field Generator Apparatus
With particular reference to FIG. 3, in regard to the
stimulation field generator apparatus 30 mentioned above,
an apparatus 30 is provided to electrically generate a stimu-
lation field of predetermined profile 10. The apparatus 30
may include several components including: 1) a power
source 31, 2) a control component 32, and 3) a transmission
component 33. The apparatus 30 is effectively tuned via an
electrical signal of predetermined profile to subsequently
deliver a stimulation field of predetermined profile 10 to
preferentially stimulate the biochemical cellular and sub-
cellular molecular responses to trigger the activation of
known mammalian genes responsible for the restoration,
repair, maintenance, or any combination of cartilage and
bone.
With continued reference to FIG. 3, the power source 31
supplies an electrical current to the control component 32
wherein the supplied electricity flows through the transmis-
sion component 33 thereby emitting a magnetic field 34.
Multiple embodiments of a power source exist. For example,
the power source 31 may comprise a battery; a power
converter that converts one form of electrical power to
another desired form and voltage (e.g., a device that converts
120 or 240 volt AC supplied by a utility company to a
well-regulated lower voltage DC for electronic devices; low
voltage, low power DC power supply units are commonly
integrated with the devices they supply, such as computers
and household electronics); a switched-mode power supply;
a linear regulator, a rectifier; a high capacity capacitance
power source; an electrical outlet power source; or any
combination.
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With continued reference to FIG. 3, the control compo-
nent 32 of the apparatus 30 is used to produce a desired
electrical signal, thereby in combination with the power
source 31 and transmission component 33, produces a
5 stimulation field of predetermined profile 10. The resultant
stimulation field is further induced to a target tissue or ROI
21 by the transmission component 33, which will be dis-
cussed later. Multiple embodiments of a control component
32 exist. For example, the control component 32 may
io comprise a voltage or amperage driven signal generator as
known as a function generator, arbitrary waveform genera-
tor, digital pattern generator, pulse generator, or frequency
generator; computerized dongle circuitry with integrated
firmware and software; a conductor; an amplifier; a sensor;
15 a microprocessor; or any combination.
With continued reference to FIG. 3, the transmission
component 33 delivers the stimulation field of predeter-
mined profile to the target area in the proper field density.
Multiple embodiments of a transmission component 33 are
20 available. For example, in an embodiment, the transmission
component 33 comprises a wire, wherein the wire is wound
into a coil about a core, wherein the turns of the wire sit
substantially side-by-side. When an electrical current is run
through the wire, an electrically generated magnetic field or
25 electromagnetic field passes through the center of the coil.
An alternating current may be employed to thereby generate
an electromagnetic field profile that alternates with respect
to direction. Multiple embodiments exist in regard to the
shape and design of the coil. For example, the coil may form
30 the shape of a straight tube; a helix (similar to a corkscrew)
such as a solenoid; a solenoid that is bent into a donut shape
(i.e., a toroid); or any combination. The transmission com-
ponent may also comprise a container of a predetermined
shape and size wherein the wire is radially disposed on the
35 container thereby forming the coil. Still further, in an
embodiment, the transmission component may also com-
prise a sleeve 20 capable of wrapping around an appendage
associated with a mammalian physiology wherein the ROI
21 is associated with said mammalian physiology.
4o Resultant Time-Varying B-Field
In an embodiment, the stimulation field generator appa-
ratus 30 is tuned to deliver a stimulation field of predeter-
mined profile 10 to preferentially stimulate the biochemical
cellular and sub-cellular molecular responses to trigger the
45 activation of known mammalian genes responsible for the
restoration, repair, modification, and maintenance of carti-
lage and bone. Production of the desired profile is accom-
plished by controlling the electricity transferred within the
stimulation field generator apparatus 30. As discussed, the
50 electricity or electrical flow is controlled by the control
component 32. The control component 32 manages the
electricity in terms of an electrical signal. An electrical
signal may be representative of a voltage, current, or both
and conveys time-based information. Further, in an embodi-
55 ment, additional management of the electrical signal may be
conducted to normalize the total energy; to selectively
modulate the resultant profile or waveform; to normalize the
profile's duty cycle, rising slew rate, falling slew rate, etc.;
or any combination.
60 With particular reference to FIG. 1, in an embodiment, a
resultant simulation field of predetermined profile 10 is
comprised of a substantially biphasic, square waveform. In
an embodiment, a substantially biphasic, square waveform
comprising a frequency in the range from about 9 Hz to
65 about 200 Hz may be employed. Further, a resultant profile
with the following FOMs may be employed: a B-Field
magnitude from about 0.6 G to about 200 G; a rise time from
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13
about 125 µs to about 1 ms; a rising slew rate from about 2.0
kG/s to about 50.0 kG/s; a fall time from about 125 µs to
about 1 ms; a falling slew rate from about 5.0 kG/s to about
50.0 kG/s; and a duty cycle of between 65-80% (and a
subsequent dwell time of between 20-35%). Additional 5
FOMs may be employed such as wavelength, exposure
duration, etc. FIG. 1 illustrates a time-varying stimulation
field profile for a stimulatory waveform for use in bone and
tissue healing according to an embodiment of the present
innovation. 10
Rotating Wall Vessels
As described above and with particular reference to FIG.
4, RWVs 40 were used and comprised a base unit 41, a
controller unit 42, and a culture vessel (aka vessel) 43. The
RWV base unit 41 makes up the mechanical portion of the 15
RWV 40. Briefly, the base unit contains a small air pump to
provide circulation along the spin filter in the center of the
culture vessel, and a stepper motor designed to spin the
weight of all culture vessels. The RWV controller unit 42
houses electronics specifically created to energize the step- 20
per motor within the base unit 41 to a consistent and
calibrated rate, providing for equal rotation speeds between
set ups so that each unit in service can be spun at identical
rates. The RWV culture vessel 43 may be comprised of a
Slow Turning Lateral Vessel (STLV) or a High Aspect 25
Rotating Vessel (HARV). Cell samples 44 are contained in
the culture vessel 43. Cell samples 44 may comprise chon-
drocytes, nucleus pulposus, osteoblasts, osteoclasts, osteo-
cytes, associated tissue, or any combination. Each STLV is
comprised of a base, a barrel, a center core for oxygenation, 30
a cap with syringe ports, and a fill plug. To offset the
potential damage to cells from off-gassing, new HARVs and
STLVs must be detoxified in a procedure involving ethanol
and autoclaving before first use.
Human Chondrocytes 35
In the laboratory tests, the HCH's were comprised of
articular chondrocytes from donors ranging in age from
50-85, and both male and female donors. These are primary
cell populations not established or immortalized cultures.
Seven male lines and seven female lines were studied. Each 40
individual donor was cultured in 2D and expanded until a
minimum of 5x107 cells could be cryopreserved. Following
initial, individual expansion, one vial of each donor was
combined into a pool, keeping male donors separate from
female donors, and expanded in 2D until an additional 45
1x108 cells in pool could be cryobanked. This combined
pool never exceeded passage 7. One should not lose the
primary characteristics of the cells in culture and therefore
effort was expended into maximizing the number of cells
available while minimizing the number of ex-vivo passages. 50
Additionally, by banking as individuals first, then creating a
pool, this technique provides the capability to "go back" and
create additional vials of pooled cells if experimentation
focus expands. The result of this effort was an additional
4.5x108 cells per sex or 9x108 total cells. 55
Human Osteoblasts
In laboratory testing, human osteoblasts (HOBS) were
cryopreserved. Again, the HOBS were received from older
donors, in this case ranging in age from 50 to 59 and from
both male and female donors. Like the HCH, each lot/donor 60
was expanded and banked as an individual, and then com-
bined by sex into multi-donor pools, yielding a pool of five
male donors and an additional pool of five female donors.
Cell Growth Media
Cell growth media, GTSF-2 is a tri-sugar, double-buffered 65
media custom formulated on an L-15/Alpha-MEM base.
Cells grown in two dimensions (2D) in standard flasks or
14
plates are exposed to such an unnatural condition that their
growth requirements are skewed as compared to in vivo.
Hence, just about any glucose-containing, single-buffered
isotonic salt solution will sustain them with minor excep-
tions as to primary, transformed, transfected or immortalized
cell status. The RWV however creates a more in-vivo like
environment. Cells are largely free from the pull of gravity
and fluid shear, and are able to fully express their natural
DNA encoded characteristics. That is, they are able to
differentiate and develop cellular structures similar to or
even exactly like their in-vivo counterparts. With a more
complete growth capability, the need for a more complete
media arises. GTSF-2 provides this complete media utilizing
glucose, galactose and fructose as simple and increasingly
complex energy sources, as well as HEPES and NaHCO3
(sodium bicarbonate) to ensure pH remains as close to
physiologic normal as possible even in the most growth-
active cultures. GTSF-2 is available in commercial formu-
lations via their "specialty media" group as DPMI 40%
MEM ALPHA MOD/60% L-15, catalog number
SH3A099.0 L
Two-Dimensional (2D) Culturing Techniques
In order to preserve as many vials of low passage cells as
possible and extend the life of the cryo-pool of cells to
accommodate any future needs, a single vial of frozen HCH
or HOB pooled cells is thawed to initiate cells for bioreactor
experiments. From a single 1 x107 cells/vial unit, we are able
to expand into as many as 2x108 cells, enough cells to
populate twelve STLVs, without passage beyond p7. Stan-
dard culturing techniques are used. T-flasks purchased from
Corning and GTSF-2 media with 10% FBS are used to
expand the HOB or HCH cells sufficiently to meet the
required numbers for the designed experiment. As the cell
population within the flask reaches a cell density of approxi-
mately 75-80%, cells are passaged into a new flask using
standard trypsinization techniques at a density roughly 25%
of the previous flask. In other words, one flask is passaged
into four. This continues until enough flasks are available to
yield the necessary number of cells. It should be noted that
continued growth of primary cells is difficult and time
consuming as normal cells are not known to be sustained in
2D culture for prolonged periods.
Microcarrier Preparation
Several different microcarrier substrates are available to
suit the need of the tissue being recapitulated. For example,
PGA (polyglycolic acid), cyclodextran, collagen and gelatin
are exemplary forms of microcarrier substrates. In an
embodiment, gelatin microcarriers, from Sigma-Aldrich (St.
Louis, Mo.), called Cultispher were employed. Cultispher is
a macroporous gelatin bead, coated with gelatin and the
increased surface area allows for better cell density with a
lighter cell load. Cultispher is provided as a dry powder and
weighed out in milligrams based on the culture. Roughly 3
mg/ml into a 55 ml STLV is sufficient growth space for HCH
and HOB cultures. Once the desired amount is weighed, the
microcarriers are placed into a small, autoclavable jar and
phosphate buffered saline (PBS) is added in sufficient quan-
tity so that they can rehydrate properly. The microcarriers
are allowed to "soak" in PBS overnight. The following day
the microcarriers are autoclaved to ensure sterility. After
autoclaving, they must be refrigerated overnight before use.
Initiation of Three-Dimensional (3D) Cultures
The quantity of cells and microcarriers used in any of the
culture vessels is dependent on a number of factors. For the
laboratory tests, the HCH and HOB are primary cells. As
such they require a starting cell density considerably higher
than that of a transformed or transfected cell lines. Addi-
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tionally, in order for the RWV to work properly, cell density
in relation to spatial and fluid limitations must be consid-
ered. The balance is adding enough cells for the crucial,
initial cell-cell interactions that will establish the culture but
not adding so many such that towards the end of the culture
period the cell density is too great to be supported in the fluid
volume and head space of the vessel. After a few limited
trials, it was determined that an initial seeding density of
3x105 cells/ml/vessel was a good balance for HCH and
HOB cells. Using standard trypsinization techniques, the
HCH or HOB cells were removed from the 2D flasks used
to expand the HCH or HOB. The HCH or HOB cells were
stored in media while performing cell counts. In an embodi-
ment, hemacytometers and trypan exclusion techniques
were used to determine cell counts. Once the number of cells
per mL is determined, a predetermined amount of the cells
were loaded into the vessel to equal the desired concentra-
tion. Next, pre-measured, pre-sterilized microcarriers were
added. Finally, the remaining volume with GTSF2 media
was added. After all culture components are loaded, air and
all subsequent air bubbles were removed, and the vessel
pressurized. This is accomplished via the syringe ports on
the top of the vessel. By filling a syringe with media and
repetitively squirting that media into the vessel while pulling
air out, all dead/air space in the vessel can be filled. After all
the bubbles have been removed in this manner, putting
pressure on the fluid in the syringe creates pressure within
the vessel. The vessels were subsequently pressurized and
capped off. The vessel is now ready to be mounted on the
base unit of the RWV.
3D Culture Maintenance
Generally speaking, the cultures are not fed within the
first 48 hours after initiation. This allows the cells time to
bind with the microcarriers and begin to produce the pro-
teins responsible for cell-cell communication and adhesion.
Feedings thereafter are determined via I-STAT (Abbott
Labs, Princeton, N.J.), a hand-held portable blood gas ana-
lyzer which is used in hospitals and clinics worldwide. The
analysis it performs is dependent on the cartridge used. For
culturing purposes, Na+ and Cl+ ions present in the super-
natants are an indicator of cell metabolism in that NaCl is
cleaved during uptake. Glucose is also notable. Glucose is
one of three sugars in GTSF-2 and the only one that can
currently be analyzed consistently. It is a primary energy
source for the cells and the quantity used in any period of
time between feedings provides information on the activity
level of the cells. BUN (blood urea nitrogen) readings on the
I-STAT correlate with stress levels within the culture.
NaHCO3 (sodium bicarbonate) levels provide information
about the quantity of acid produced as a result of metabolic
activity. These various ions plus other parameters the
I-STAT measures, are essential to making good decisions as
to quantity and frequency of feeding of the cultures. The
ultimate goal is to maintain as physiologic normal within the
bioreactor. A pH of 7.2, roughly 80-100 mg/dL of glucose,
and adequate but not excessive salt and bicarbonate to
balance the solution are achieved to maintain proper isoto-
nicity. Deviations measured each 24 hour period from nor-
mal and the time it takes for them to occur is how the
maintenance schedule for the cultures are determined.
Analytical Techniques Utilized Post-Experiment
Light microscopy is also used in conjunction with immu-
nohistochemistry (IHC). Cells are embedded in a paraffin
matrix, then thin layers are cut and mounted on slides. These
slices are then stained with an antibody conjugated to a color
of some kind or to a flourochrome to make the binding site
visible. The antibodies can be to a cell type specific antigen
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found only in that specific cell. The antibodies can also be
to a protein or cytokine product being produced by the cell.
The slides with the tissue slices mounted on them are then
viewed via a microscope either light or confocal and
5 photographed for analysis and publication. Concentration of
the color or flourochrome on the cell is indicative of the
quantity of the antigen or protein in question. Dark coloring
means high binding and high presence whereas light color-
ing is a reduced presence and low binding. IHC is generally
io considered a "qualitative" assessment however and other
techniques are used to "quantify" marker expression. A
portion of tissue like assemblies are aliquoted, washed 3x
with filter-sterilized water, aspirated, and fixed in a final
concentration of 2% Glutaraldehyde/3% Formaldehyde pre-
15 pared in PBS. The samples are fixed for a minimum of 24 hrs
at 4° C. overnight. The samples are flushed in triplicate with
filter-sterilized deionized water to remove salts and then
transferred for observation and imaging to a FEI XL30
Environmental Scanning Electron Microscope. Genetic
20 array analyses are performed on experiments after each
major change in parameters or change in cell type.
Laboratory Testing
The inventors have conducted several studies on the
effects of time-varying stimulation fields on cellular pro-
25 cesses. For example, in a study, a mixed population of
human chondrocytes (HCH) was created and banked from
patient samples ranging in age from 58 through 81 years.
These samples were selected due to their indications of early
stage osteoarthritis. A male test population was exposed to
3o a stimulation field of predetermined profiles comprising a
predetermined B-Field magnitude and waveform shape,
produced by an electrical signal in a continuous manner for
about 30 days in a RWV. FIG. 5 illustrates an exemplary
set-up incorporating the integration of a RWV and a stimu-
35 lation field generator. Cellular gene expression analyses
comprised of fold change analyses were accomplished by an
AFFYMETRIX Gene Array survey of 47,000 human genes
(U133 Plus 2.0 Chip) using the HCH samples exposed to the
stimulation field as well as control HCH samples. The
40 expression results were confirmed by a Reverse Tran-
scriptase Polymerized Chain Reaction (RT-PCR) or
LUMINEX Assays. There was a difference between the
types of regulated genes. The experiment was repeated with
two sets of HCH samples were each exposed to separate
45 stimulation fields of predetermined profile (one stimulation
field for each set of samples). The B-Field magnitude for
each stimulation field was different in this experiment. After
a similar gene array survey, there was a difference between
the types of regulated genes exposed to the different stimu-
50 lation fields. The experiment was repeated with two HOB
samples were exposed to separate stimulation fields of
predetermined profile (one stimulation field for each set of
samples). The B-Field magnitude for each stimulation field
was substantially equal in this experiment. It was anticipated
55 that any cellular activity, expressed in cellular gene expres-
sion analysis, would be relatively equal because the related
art suggests that a B-Field's magnitude is the determinative
variable. However, the experiment yielded unanticipated
results. Specifically, a subsequent gene array survey
6o revealed significant differences in gene expressions between
the two cell samples. Differences in the type of regulated
genes exposed to the different stimulation fields were
observed. As an example, the gene array survey results from
these experiments indicate significant differences between
65 stimulation field profiles in regard to potential use for
osteoarthritis treatment. The results clearly indicate prefer-
ential regulation of cellular mechanisms identified with
US 9,896,681 B2
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human chondrogenesis, osteogenesis, and extracellular
matrix (ECM) deposition from a set of specific signals
wherein B-Field magnitude is not the determinative vari-
able. Rather, the shape of a stimulation field profile (i.e.,
waveform) and FOMs (in addition to a B-Field magnitude)
are also influential factors.
In an embodiment, a mixed population of human chon-
drocytes described above was expanded in culture flasks.
First, tissue-like-assemblies (TLAs) were constructed from
normal human chondrocytes. From these TLAs, cell samples
were grown (i.e., expanded) in two-dimensional (21)) cul-
ture flasks. The cell sample population was derived from
several patient samples wherein these samples were pooled
and gender isolated. The subsequent cultures were estab-
lished in a GTSF-2 growth medium. GTSF-2 growth
medium is a basal cell culture medium. In addition to
traditional growth-factors, GTSF-2 contains a blend of three
sugars (glucose, galactose, and fructose) at their physiologi-
cal levels. The cultures were removed from the 2D flasks by
trypsin-EDTA and counted.
Exposures of these chondrocyte cell samples to a prede-
termined time schedule of stimulation fields of predeter-
mined profiles were performed in the following manner. A
known cell volume was inoculated into at least three rotating
wall vessels (RWVs) for each sample set and a control
sample set wherein the RWVs are associated with a rotating
bioreactor, such as a RCCS-1 system, which is a commercial
unit manufactured by Synthecon, Inc. RWVs were inserted
into a predetermined coil designed to deliver a stimulation
field of predetermined profile comprised of a predetermined
set of FOMs. The RWVs contained a predetermined volume
of microcarriers. Electricity was subsequently supplied to
the coil in accordance with a predetermined profile. In the
simulated microgravity environment of the RW V, the human
chondrocyte and human osteoblast cells adhered to new
growth matrices and began to multiply in cell-bead aggre-
gates. The cell-bead aggregates developed for a predeter-
mined exposure time or plurality of exposure time sequences
wherein multiple embodiments exist thereto (e.g., for about
30 days; between about 1 hour and about 720 hours; for 24
hours on, 24 hours off, repeat for a total of 30 days; etc.).
Cell growth observations and analyses were then per-
formed using the sample set(s) which were contained in at
least 3 RWVs per sample set and a control sample set also
comprised of samples contained in at least 3 RWVs. Gene
analyses were accomplished by an AFFYMETRIX
GENECHIP Human Genome U133 Plus 2.0 Array, RT-PCR,
or LUMINEX Assay. A survey of the entire human genome
of approximately 47,000 human genes exposed to multiple
stimulation field profiles as regulated by multiple electrical
signals was conducted.
Similar experiments were performed with human osteo-
blasts. In addition, the same result in regard to stimulation
fields of different profiles inducing regenerative (e.g., ana-
bolic) vs. reparative (e.g., catabolic) genes was observed but
with increased genetic activity. A sample set of experimental
results is as follows wherein said sample set are provided for
the purpose of illustrating the development of the innovation
as well as various embodiments of the innovation and are not
meant to limit the present innovation in any fashion.
Example 1 (Human Chondrocytes)
In a first experiment, a first set of HCH cell samples
contained in at least 3 RWVs were exposed to a first
time-varying stimulation field of predetermined profile com-
prised of substantially a biphasic, square wave with a
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frequency of about 10 Hz; a wavelength of about 500 ms; a
rising slew rate between about 0.2 T/s (2.0 kG/s) to about
0.45 T/s (4.5 kG/s); a falling slew rate between about 0.45
T/s (4.5 kG/s) to about 1.5 T/s (15.5 kG/s); a dwell time of
5 about 10% after each burst; a duty cycle of about 80% on
and about 20% off; and a resultant B-Field magnitude of
about 5.9 µT (0.059 G). The experiment was conducted at 10
Hz. For reference purposes, the frequency of Earth's geo-
magnetic field is 7.83 Hz, thus the experiment satisfies the
l0 
criteria of being appreciably different from the background
magnetic field. Exposure was continuous for the length of
this experiment wherein said length was about 30 days or
about 720 hours. Gene analysis comprising a fold change
15 analysis as describe above was conducted for the HCH cell
samples exposed to the first time-varying stimulation field.
Exemplary results from said gene analysis associated with
the first time-varying stimulation field are provided in Table
2 below.
20 Generally, the related art consensus teaches that a field
strength (either electric or magnetic) should be sufficiently
powerful enough to penetrate deep enough inside cells to
cause the desired effect. In order for this to happen the
applied energy levels must be sufficiently high to penetrate
25 deep enough inside cells, otherwise only a minimal and
superficial effect can be expected. Electric fields are more
susceptible to shielding effects as compared to magnetic
fields. As described above, the laboratory set-up comprised
the use of at least 3 RWVs for the first set of HCH samples
30 wherein the at least 3 RWVs were each enclosed within wire
coils designed to generate a magnetic field. Thus, the level
of interference was minimized and the relatively low
B-Field magnitude of the first time-varying stimulation field
did result in the regulation of over 2000 genes. However,
35 consideration as to applying an equivalent "effective"
B-Field magnitude to a mammalian subject may require
increasing the B-Field magnitude by a predetermined ampli-
fication factor of predetermined value or "gain" thereby
requiring the creation of a dose response curve. This ampli-
40 fication factor or gain may be required due to differences in
the level of interference associated with the inventors'
laboratory set-up and a mammalian physiology (e.g., skel-
etal structure comprised of bone). The inventors stipulate
that translation of the "optimum" effective field and condi-
45 tions must take into account the systemic dampening
encountered by the application to an entire physiology.
An unanticipated observation was made in regard to the
type of genes that were regulated in that genes normally
associated with a regenerative function (i.e., anabolic genes)
50 were up-regulated at a much higher percentage as compared
to genes associated with a reparative function (i.e., catabolic
genes). In some cases, genes exposed to the first time-
varying stimulation field were down-regulated thereby
resulting in a catabolic effect or up-regulated thereby result-
55 ing in an anabolic effect, or vice-versa. In an embodiment,
a set of genes may be selected based on known function(s).
The fold change for each gene is said set may be analyzed
and determined to be consistent with up-regulation, down-
regulation, or no regulation. Each regulated gene may be
60 subsequently analyzed for an anabolic effect, catabolic
effect, or no differential regulation (NDR). In a further
embodiment, a relative value for each anabolic and catabolic
effect may be assigned. And, the entire set of anabolic and
catabolic effects may be compared in terms of the relative
65 values of each effect. Thus, the resultant anabolic vs. cata-
bolic effects may be determined. It should be noted that
many of the genes (anabolic) up-regulated in this experiment
US 9,896,681 B2
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are associated with embryonic development (Lanza, 2000).
Table 1 provides a summary of said effects for the first
experiment.
20
TABLE 2-continued
TABLE 1 5
# Genes # of Anabolic # of Catabolic Gene Family
Stimulation Field Regulated Gene Effects f Gene Effects f
IL-4 inducible 1 (IL-4Il) (TH2
First Time-Varying 2021 37 11 induction)
Stimulation Field 10 IL-8
IL-6
Tln exemplary results in accordance to Table 1. IL-24
IL-17A
As observed in Table 1, the results for the first time- Thrombospondin Family(COMPS)
varying stimulation field are indicative of anabolic or regen-
erative effects. Table 2 provides additional details with 15 Thrombospondin 2 (THBS2)
respect to this observation wherein anabolic and catabolic Thrombospondin 3 (THBS3)
effects are identified. Laminin Family
Laminin Beta 1 (LAMBI)
TABLE 2 Laminin Beta 2 (LAM132)20 Laminin Gamma 1 (LAMCI)
Anabolic or Proteoglycan Family
Catabolic Effect
Fold Increase/ of Genes Biglycan (BGN)
Decrease for Associated with Aggrecan (ACAN)
First Time-Varying Chondrocyte PAPLN (Papilin)
Gene Family Stimulation Field Development 25 Chondroitin Sulphate
Proteoglycan 4 (CSPG4)
WNT Family Hyalmonan and Proteoglycan
Link protein 1 (HAPLN 1)
WNTSB +3.43 Anabolic Proteoglycan 4 (PRG4)
WSPI +3.41 Anabolic Collagen Family
WSP2 +3.03 Anabolic 30
Bone Morphogenetic Protein Collagen, Type 1, Alpha 1
(BMP) Family (COL1A1)
Collagen, Type 3, Alpha 1
BMP2 -8.63 Catabolic (COL3A1)
BMP6 -4.56 Catabolic Collagen, Type 4, Alpha 4
Forkhead Box (FOX) Family 35 (COL4A4)
Collagen, Type 5, Alpha 1
FOXFI -3.32 Catabolic (COL5A1)
FOXN3 -4.00 Catabolic Collagen, Type 5, Alpha 2
Sex Determining Region Y (COL5A2)
(SRY) SOX Family Collagen, Type 6, Alpha 2
(COL6A2)
SOX9 (SRY-box 9) -3.03 Catabolic 40 Collagen, Type 8, Alpha 2
SOX10 (SRY-box 10) -2.91 Catabolic (COL8A2)
Parathyroid Hormone (PTH) Collagen, Type 12, Alpha 1
Family (COL12A1)
Collagen, Type 16, Alpha 1
PTHLH (PTH-like hormone -11.00 Catabolic (COL16A1)
[LH]) 45 Collagen, Type 21, Alpha 1
Latent Transforming Growth (COL21A1)
Factor (TGF) Family (ECM) Collagen, Type 27, Alpha 1
(COL27A1)
Latent TGF Beta Binding +6.54 Anabolic Insulin (INS) Family
Protein 2
Latent TGF Beta Binding +3.71 Anabolic 50 Insulin-Like Growth Factor
Protein 3 (IGF) Binding Protein (BP) 1
Integrin Family (Cell Sulfur- IGFBPS
Based [Sur]: ECM) INS
Integrin beta-like 1 (ITGBLI)
with epidermal growth factor
(EGF)-like repeat domains
Integrin beta 2 (ITGB2)
complement component 3,
receptor 3, and 4 subunit
Integrin beta 3 binding
protein (beta3-endonexin)
(IrGB3BP)
Interleukin (IL) Family (Cellular
Cytokine Response)
IL-32
IL-33 (IL-1 super family)
IL-1 receptor (IL-1R1) (IL-1
super family)
Anabolic or
Catabolic Effect
Fold Increase/ of Genes
Decrease for Associated with
First Time-Varying Chondrocyte
Stimulation Field Development
+3.01 Anabolic
-4.82 Anabolic
-2.66 Anabolic
-3.41 Catabolic
-2.87 Anabolic
+4.79 Anabolic
+3.73 Anabolic
+3.14 Anabolic
+2.91 Anabolic
+2.82 Anabolic
+6.45 Anabolic
+3.81 Anabolic
+3.38 Anabolic
+3.16 Anabolic
+4.66 Anabolic
+2.85 Anabolic
+32.67 Anabolic
+4.23 Anabolic
+3.53 Anabolic
+7.52 Anabolic
+6.54 Anabolic
+4.00 Anabolic
+3.63 Anabolic
+3.93 Anabolic
+3.68 Anabolic
+5.54 Anabolic
+5.06 Anabolic
-13.18 Catabolic
-5.03 Catabolic
-2.89 Catabolic
+6.45 Anabolic
55 Table 2 shows several select genes experienced up or
down-regulation in the first experiment. For example, BMPs
+4.38 Anabolic
are a group of growth factors also known as cytokines
originally discovered for their ability to induce the formation
+2.93 Anabolic of bone and cartilage and are also considered to constitute a
60 group of pivotal morphogenetic signals, orchestrating tissue
architecture throughout the body. BMP2 was down-regu-
lated in the first experiment. BMP2 acts as a disulfide-linked
homodimer and induces bone and cartilage formation and
+3.92 Anabolic plays a key role in osteoblast differentiation. Further, BMP2
+3.39 Anabolic
+2.95 Anabolic 65 is beneficial in the treatment of a variety of bone-related
conditions including delayed union and non-union. In this
experiment, the down-regulation of BMP2 represents a
US 9,896,681 B2
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catabolic effect. Particularly as the goal was to enhance the
growth of human chondrocytes. A similar application of a set
of FOMs will result in the up-regulation of BMPs. Thus, this
experiment demonstrated that changes in FOMs as well as
overall B-Field can significantly change outcomes. As
another example, the up-regulation of the genes in the
collagen family represents an anabolic effect.
Example 2 (Human Chondrocytes)
In a second experiment, a second set of HCH cell samples
contained in at least 3 RWVs were exposed to a second
time-varying stimulation field of predetermined profile com-
prised of substantially a biphasic, square wave with a
frequency of about 10 Hz; a wavelength of about 500 ms; a
rising slew rate between about 0.2 T/s (2.0 kG/s) to about
0.45 T/s (4.5 kG/s); a falling slew rate between about 0.45
T/s (4.5 kG/s) to about 1.55 T/s (15.5 kG/s); a dwell time of
about 10% after each burst; a duty cycle of about 80% on
and about 20% off, and a resultant B-Field magnitude of
about 65 µT (0.65 G). A third set of HCH cell samples
contained in at least 3 RWVs were also separately exposed
to a third time-varying stimulation field of predetermined
profile comprised of a substantially monophasic, delta wave
with a frequency of about 15 Hz; a duty cycle of about 30%
on and about 70% off; and a resultant B-Field magnitude of
about 250 µT (2.5 G). The third time-varying stimulation
field is generally illustrated in FIG. 2. Note that the wave-
form represented in the third time-varying stimulation field
may be designated a "pulse" or "burst" due to both its shape
and wavelength (aka a "pulsed time-varying stimulation
field"). Exposures were continuous for the length of this
experiment wherein said length was about 30 days or about
720 hours. Equivalent equipment was used for the second
and third sets of HCH cell samples. However, it is noted that
different transmission components (e.g., antennae) were
utilized between the first and second experiments.
These results were indicative of varying cellular effects
due to substantive differences in the B-Field magnitudes
with respect to the second and third time-varying stimulation
fields as well as between the first and second time-varying
stimulation fields. Hence, the results of the second experi-
ment were, on its face, consistent with consensus related art
publications that described a B-Field magnitude as compris-
ing the determinative control factor for cellular effects. In
other words, as can be observed in Table 4 and Table 2, there
are substantive differences in the resultant gene expressions
between human chondrocyte cellular exposure to the second
OW
and third time-varying stimulation fields as well as between
the first and second time-varying stimulation fields. For
example, the total number of regulated genes between the
first and second time-varying stimulation fields (2021 vs.
5 1097) constituted a 46% decrease in regulated genes. It was
not anticipated that such a substantive decrease in regulated
genes would occur. Rather, because consensus related art
publications disclose that a B-Field magnitude is the deter-
minative control value and a high enough B-Field magnitude
is required to stimulate cellular effects, it was anticipated
10 
that the total number of regulated genes would increase. The
inventors hypothesized that the substantive decrease in
regulated genes was related to the fact that different trans-
mission components were used in regard to the first and
second experiments. In terms of net effects, the results of the
15 second experiment validated the inventors' observations in
regard to anabolic vs. catabolic effects associated with the
second time-varying stimulation field. Table 3 represents a
summary of the second experiment in regard to gene expres-
sion.
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TABLE 3
# Genes # of Anabolic # of Catabolic
Stimulation Field Regulated Gene Effects* Gene Effects*
25 Second Time-Varying 1097 52 3
Stimulation Field
Third Time-Varying 850 12 15
Stimulation Field
*In exemplary results in accordance to Table 4.
30
As can be observed in Tables 3 and 4, the anabolic and
catabolic effects associated with the second and third time-
varying stimulation fields were substantively different. Yet
there is a commonality between the first and second stimu-
lation fields or specifically, the disproportionally large num-
35 ber of anabolic vs. catabolic gene responses. The exemplary
results for the second time-varying stimulation field are
indicative of anabolic or regenerative effects. Conversely,
the exemplary results from the third time-varying stimula-
tion field are relatively neutral in regard to anabolic vs.
4o 
catabolic effects while the total B-Field is much higher (65
µT vs. 250 µT). This result is not expected given prior art
publications and was therefore unanticipated. Specifically
there should be much greater effects at 250 µT as compared
to 65 µT, however this was not the case. A comparison of the
45 
exemplary results associated with the two field profiles are
provided in Table 4 below:
TABLE 4
Anabolic or Anabolic or
Fold Catabolic Fold Catabolic
Increase/ Effect of Increase/ Effect of
Decrease for Genes Decrease for Genes
Second Time Associated Third Time Associated
Varying with Varying with
Stimulation Chondrocyte Stimulation Chondrocyte
Gene Family Field Development Field Development
WNT Family
WNTSB +00.0 NDR —3.43 Catabolic
WSPI +00.0 NDR +3.25 Anabolic
WSP2 +00.0 NDR —2.91 Catabolic
Bone Morphogenetic Protein
(BMP) Family
BAMBI +5.03 Anabolic +2.95 Anabolic
BMPI +3.32 Anabolic —3.98 Catabolic
BMP6 +2.95 Anabolic +00.0 NDR
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TABLE 4-continued
Gene Family
Anabolic or
Fold Catabolic
Increase/ Effect of
Decrease for Genes
Second Time Associated
Varying with
Stimulation Chondrocyte
Field Development
Anabolic or
Fold Catabolic
Increase/ Effect of
Decrease for Genes
Third Time Associated
Varying with
Stimulation Chondrocyte
Field Development
Forkhead Box (FOX) Family
FOXQI -4.69 Catabolic +00.0 NDR
FOXN3 -3.61 Catabolic +00.0 NDR
FOXCI +00.0 NDR -3.32 Catabolic
Sex Determining Region Y
(SRY) SOX Family
SOX4 (SRY-box4) +2.91 Anabolic +2.91 Anabolic
SOX9 (SRY-box 9) +00.0 NDR -4.66 Catabolic
Parathyroid Hormone (PTH)
Family
PTHLH (PTH-like hormone +4.03 Catabolic -6.59 Anabolic
[LH])
Transforming Growth Factor
(TGF) Family
TGF-Beta 1 +3.03 Anabolic +00.0 NDR
TGF-Beta 2 +4.41 Anabolic +00.0 NDR
Latent TGF Beta Binding +4.26 Anabolic +2.89 Anabolic
Protein 3
Integrin Family (Cell Sur:
ECM)
Integrin Alpha 8 (ITGA8) +9.99 Anabolic +00.0 NDR
Integrin Alpha 4 (ITGA4); +4.41 Anabolic +00.0 NDR
CD49D)
Integrin Alpha 6 0.00 NDR +3.23 Anabolic
ITGA6
Integrin Beta 3 (ITGB3) +3.63 Anabolic +00.0 NDR
Integrin Beta 2 (ITGB2) +3.71 Anabolic +00.0 NDR
Integrin Alpha 2 (ITGA2); +3.34 Anabolic +00.0 NDR
CD49B
Integrin beta-like 1 +5.46 Anabolic +00.0 NDR
(ITGBLI) with epidermal
growth factor (EGF)-like
repeat domains
Interleukin Family (Cellular
Cytokine Response)
Interleukin 33 (IL-33)(IL-1 +8.74 x 106 Anabolic +00.0 NDR
super family)
Interleukin 26 (IL-26)(IL-10 +4.59 Anabolic +00.0 NDR
Family)
Interleukin 8 (IL-8) +4.82 Anabolic +00.0 NDR
Interleukin 6 (IL-6) +2.89 Anabolic +00.0 NDR
Interleukin (IL-11) 0.00 NDR -2.91 Catabolic
Thrombospondin Family
Thrombospondin 1 (THBS1) +4.61 Anabolic +00.0 NDR
Thrombospondin 2 (THBS2) +3.73 Anabolic +00.0 NDR
ADAM metallopeptidase +3.18 Anabolic -3.72 Catabolic
with thrombospondin type 1
motif (ADAMTSI)
ADAM metallopeptidase +4.00 Anabolic -2.89 Catabolic
with thrombospondin type 5
motif (ADAMTSS)
Laminin Family
Laminin Beta 1 (LAMBI) +00.0 NDR +3.78 Anabolic
Proteoglycan Family
Biglycan (BGN) +3.46 Anabolic +00.0 NDR
Aggrecan (ACAN) +3.81 Anabolic +00.0 NDR
PAPLN (Papilin) +00.0 NDR +4.79 Anabolic
Hyalmonan and +5.03 Anabolic +00.0 NDR
Proteoglycan Link protein 1
(HAPLN 1)
WE
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TABLE 4-continued
Anabolic or Anabolic or
Fold Catabolic Fold Catabolic
Increase/ Effect of Increase/ Effect of
Decrease for Genes Decrease for Genes
Second Time Associated Third Time Associated
Varying with Varying with
Stimulation Chondrocyte Stimulation Chondrocyte
Gene Family Field Development Field Development
Proteoglycan 4 (PRG4) +3.76 Anabolic +00.0 NDR
Leucine Proline-enriched +2.91 Anabolic +00.0 NDR
Proteoglycan (Leprecan-
Like) 1 (LEPREI)
Matrix Metallapeptidase
(MMP) Family
SMMPI (interstitial -3.39 Anabolic +5.50 Catabolic
collagenase)
MMP3 (interstitial -2.89 Anabolic +3.18 Catabolic
collagenase) stromelysin 1
MMP13 (interstitial -3.97 Anabolic +4.41 Catabolic
collagenase 3)
Tissue Inhibitor of
Metalloproteinases (TIMP)
Family
TIMP Inhibitor 3 (TIMP3) +3.03 Anabolic -4.03 Catabolic
(Sorsby Fundus Dystrophy)
Collagen Family
Collagen, Type 1, Alpha 1 +32.62 Anabolic +5.98 Anabolic
(COL1A1)
Collagen, Type 3, Alpha 1 +4.23 Anabolic +3.84 Anabolic
(COL3A1)
Collagen, Type 4, Alpha 1 +2.95 Anabolic +00.0 NDR
(COL4A1)
Collagen, Type 4, Alpha 2 +3.12 Anabolic +00.0 NDR
(COL4A2)
Collagen, Type 4, Alpha 4 +5.06 Anabolic +00.0 NDR
(COL4A4)
Collagen, Type 5, Alpha 1 +22.62 Anabolic +00.0 NDR
(COL5A1)
Collagen, Type 11, Alpha 1 +44.63 Anabolic +00.0 NDR
(COL11A1) (Cartilage)
Collagen, Type 12, Alpha 1 +3.92 Anabolic +00.0 NDR
(COL12A1)
Collagen, Type 15, Alpha 1 +22.47 Anabolic -9.71 Catabolic
(COL15A1) (Muscle and
Microvascular Deterio)
Collagen, Type 21, Alpha 1 +00.0 NDR +5.06 Anabolic
(COL21A1)
Collagen, Type 27, Alpha 1 +00.0 NDR +5.06 Anabolic
(COL27A1)
Insulin Family
Insulin-Like Growth Factor 0.00 NDR +3.94 Anabolic
(IGF) 1 (IGFI)
Insulin-Like Growth Factor +4.76 Anabolic +4.29 Anabolic
(IGF) 2 (IGF2)
IGF Binding Protein +7.78 Anabolic -52.35 Catabolic
(IGFBP) 1
IGFBP2 +13.45 Anabolic -00.0 NDR
IGFBP3 +10.70 Anabolic -3.07 Catabolic
IGFBPS +2.81 Anabolic -5.74 Catabolic
IGFBP6 0.00 NDR -3.05 Catabolic
Actin Family
Actin, Alpha 2 (ACTH) 2 +3.32 Anabolic +00.0 NDR
Actinin, Alpha 1 (ACTNI) +3.12 Anabolic +00.0 NDR
Palladin Cytoskeletal +3.23 Anabolic +00.0 NDR
Associated Protein (PALLD)
Actin/Cytoskeletal Related
Genes
Cytoskeleton-Associated +2.85 Anabolic +00.0 NDR
Protein (CKAP) 4
Catenin (Cadherin- +3.81 Anabolic +00.0 NDR
Associated Protein, Alpha
1) (CTNNAI)
26
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TABLE 4-continued
Anabolic or Anabolic or
Fold Catabolic Fold Catabolic
Increase/ Effect of Increase/ Effect of
Decrease for Genes Decrease for Genes
Second Time Associated Third Time Associated
Varying with varying with
Stimulation Chondrocyte Stimulation Chondrocyte
Gene Family Field Development Field Development
Cadherin 2, N-Cadherin +16.45 Anabolic +00.0 NDR
(Neuronal) (CDH2)
H-Cadherin (Heart) +3.27 Anabolic —2.99 Catabolic
(CDH13)
Filamin B, Beta (Actin +2.95 Anabolic +00.0 NDR
Binding Protein 278) (FLNB)
Filamin C, Gamma (Actin +00.0 NDR —2.93 Catabolic
Binding Protein 280)
(FLNC)
As can be observed in Table 4, several select genes of
interest experienced up or down-regulation in the second
experiment. It is noted that ADAMTS genes are generally
considered to be anabolic when up-regulated but catabolic
when down-regulated. As can be observed in Table 4,
ADAMTSI and 5 were both up-regulated with respect to
exposure to the second time-varying stimulation field. Con-
versely, ADAMTSI and 5 were down-regulated with respect
to exposure to the third time-varying stimulation field.
MMPs proteases are generally considered catabolic because
they breakdown tissue (a process associated with remodel-
ing and repair). When MMPs are down-regulated, catabolic
effects are suppressed thereby having in a net anabolic
effect. Conversely, when MMPs are up-regulated their cata-
bolic effects are enhanced. As can be observed in Table 4,
MMPL 3, and 13 were down-regulated with respect to
exposure to the second time-varying stimulation field. Con-
versely, MMP 1, 3, and 13 were up-regulated with respect to
exposure to the third time-varying stimulation field. BMPI
is involved in cartilage development and is related to a
regenerative function or anabolic in nature. Table 4 shows
that BMPI was up-regulated with respect to exposure to the
second time-varying stimulation field. Conversely, BMPI
was down-regulated with respect to exposure to the third
time-varying stimulation field.
Example 3 (Human Osteoblasts)
In a third experiment, a first set of HOB cell samples
contained in at least 3 RWVs were exposed to substantially
the same time-varying stimulation field profile as compared
to the second time-varying stimulation field of predeter-
mined profile in the second experiment. For clarity purposes,
this stimulation field profile will be referred to as a fourth
time-varying stimulation field of predetermined profile com-
prised of substantially a biphasic, square wave with a
frequency of about 10 Hz; a wavelength of about 500 ms; a
rising slew rate between about 0.2 T/s (2.0 kG/s) to about
0.45 T/s (4.5 kG/s); a falling slew rate between about 0.45
T/s (4.5 kG/s) to about 1.55 T/s (15.5 kG/s); a dwell time of
about 10% after each burst; a duty cycle of about 80% on
and about 20% off, and a resultant B-Field magnitude of
about 65 µT (0.65 G). A second set of HOB cell samples
contained in at least 3 RWVs were also separately exposed
to substantially the same stimulation field as compared to the
third time-varying stimulation field previously described.
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20 For clarity purposes, this pulsed stimulation field will be
referred to as the fifth time-varying stimulation field of
predetermined profile comprised substantially of a mono-
phasic, delta wave with a frequency of 15 Hz; a duty cycle
of about 30% on and about 70% off; and a resultant B-Field
25 magnitude of about 65 µT (0.65 G), wherein said B-Field
magnitude is substantially fixed in one direction (i.e., mono-
phasic). Note that in this experiment, the B-Field magni-
tudes of the fourth and fifth time-varying stimulation fields
30 were substantially equal. Equivalent equipment was used for
the first and second sets of HOB cell samples. Equivalent
equipment was used in comparison with the second and third
experiments. Exposures were continuous for the length of
35 this experiment wherein said length was about 30 days or
about 720 hours. As in the second experiment, the resultant
cellular effects between the first and second sets of HOB cell
samples were substantively different. It is noted here that
two separate gene analyses for the first and second set of
40 HOB cell samples were conducted. For the first set of HOB
cell samples, these gene analyses are defined as #1 and #2
Fold Increase/Decrease for Fourth Time Varying Stimula-
tion Field in Tables 6 and 7 below. For the second set of
45 HOB cell samples, these gene analyses are defined as #3 and
#4 Fold Increase/Decrease for Fifth Time Varying Stimula-
tion Field in Tables 6 and 7 below. A comparison of
exemplary results associated with the two separate gene
50 
analyses for each of the two field profiles are provided in the
tables below:
TABLE 5
55 # Genes # of Anabolic # of Catabolic
Stimulation Field Regulated Gene Effects Gene Effects
#1 Fourth Time-Varying 2495 87 6
Stimulation Field
#2 Fourth Time-Varying 2691 81 4
60 Stimulation Field
#3 Fifth Time-Varying 437 20 7
Stimulation Field
#4 Fifth Time-Varying 527 21 5
Stimulation Field
65
In exemplary results in accordance to Tables 6 and 7.
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TABLE 6
Gene Family
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#1 Fold with
Increase/Decrease Osteoblast
for Fourth Time and bone
Varying cell
Stimulation Field Development
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#3 Fold with
Increase/Decrease Osteoblast
for Fifth Time and bone
Varying cell
Stimulation Field Development
actin (ACTB) NDR NRE +3.3309 Anabolic
ADAM +4.0239 Anabolic +3.1776 Anabolic
metallopeptidase
domain 10 (ADAM10)
ADAM +3.1086 Anabolic NDR NRE
metallopeptidase
domain 17 (tumor
necrosis factor
interacts with TNF
alpha (ADAM17)
ADAM +9.6955 Anabolic NDR NRE
metallopeptidase with
thrombospondin type
1 motif (ADAMTS1)
apoptosis inhibitor 5 +2.9426 Anabolic NDR NRE
(API5)
B-cell CLL/lymphoma +2.9013 Anabolic NDR NRE
3 (BCL3)
B-cell CLL/lymphoma NDR NRE +2.8596 Anabolic
6 (zinc finger protein
51) (BCL6)
BCL2-associated NDR NRE +2.8730 Anabolic
athanogene 2 (BAG2)
BCL2-related protein -3.2422 Catabolic NDR NRE
At (BCL2A1)
biglycan (BGN) +17.3408 Anabolic NDR NRE
(201262sat)
bone morphogenetic +136.2100 Anabolic NDR NRE
protein 2 (BMP2)
bone morphogenetic +3.2517 Anabolic NDR NRE
protein receptor
(BMPR2)
cadherin 11 Bone +3.4967 Anabolic NDR NRE
Specific/Osteoblasts
(CDHI I)
Calcium/calmodulin- +6.0076 Anabolic NDR NRE
dependent protein
kinase (CaM kinase)
II delta (CAMK2D)
calmodulin 1 NDR NRE +2.9689 Anabolic
(phosphorylase
kinase (CALMI)
calumenin (CALU) +4.0815 Anabolic +3.5804 Anabolic
(214845sat)
cartilage oligomeric +12.1656 Anabolic -3.8106 Catabolic
matrix protein
(COMP)
CASP8 and FADD- -2.8575 Anabolic NDR NRE
like apoptosis
regulator (CFLAR)
catenin (cadherin- +4.4593 Anabolic +3.2564 Anabolic
associated protein)
(CTNNB I )
cathepsin C (CTSC) -4.2881 Anabolic NDR NRE
cathepsin O (CTSO) -2.8365 Anabolic NDR NRE
cathepsin S (CTSS) -2.9715 Anabolic NDR NRE
chondroitin sulfate +4.0672 Anabolic NDR NRE
proteoglycan 4
(CSPG4) (214297at)
clusterin Anti +19.4810 Anabolic NDR NRE
apoptosis and MMPs
(CLU)
collagen (COL12A1) +2.9218 Anabolic NDR NRE
collagen (COL15A1) -16.2926 Anabolic NDR NRE
collagen (COL1A1) +2.8683 Anabolic NDR NRE
collagen (COL3A1) +4.7532 Anabolic NDR NRE
collagen (COL3A1) +4.5715 Anabolic NDR NRE
collagen (COL4A1) +3.1465 Anabolic NDR NRE
collagen (COL4A2) +3.2012 Anabolic +2.8581 Anabolic
30
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TABLE 6-continued
Gene Family
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#1 Fold with
Increase/Decrease Osteoblast
for Fourth Time and bone
Varying cell
Stimulation Field Development
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#3 Fold with
Increase/Decrease Osteoblast
for Fifth Time and bone
Varying cell
Stimulation Field Development
collagen +3.3796 Anabolic NDR NRE
(COL4A3BP)
collagen (COL5A2) +3.6551 Anabolic NDR NRE
collagen (COL6A1) +3.0345 Anabolic +3.2741 Anabolic
collagen (COL8A1) +2.9195 Anabolic NDR NRE
cytochrome P450 +6.4062 Anabolic +3.7186 Anabolic
(CYP1B1) embryonic
development
cytochrome P450 +5.0863 Anabolic NDR NRE
(CYP24A1) Vit D3
homeostatis
endoglin (Osler- NDR NRE +2.9135 Catabolic
Rendu-Weber
syndrome 1) (ENG)
Fas (TNF receptor +3.2724 Anabolic +3.5713 Anabolic
superfamily (FAS)
fibrillin 1 (FBNI) +3.2809 Anabolic +3.7335 Anabolic
fibroblast growth -2.8473 Anabolic NDR NRE
factor 1 (acidic)
(FGF1)
fibroblast growth +4.5734 Anabolic NDR NRE
factor 18/embryonic
development, cell
growth,
morphogenesis,
tissue repair (FGF18)
fibulin 1 (FBLNI) +4.1863 Anabolic NDR NRE
forkhead box N3 +3.9116 Anabolic NDR NRE
(FOXN3)
forkhead box 01 +2.8822 Anabolic NDR NRE
(FOXOI)
forkhead box 03 +3.3640 Anabolic NDR NRE
Tumor Suppressor
(FOXO3)
(204132sat)
forkhead box 03 +3.1184 Anabolic NDR NRE
(FOXO3)
(210655sat)
forkhead box Q1 +3.3091 Anabolic NDR NRE
Function Unknown
(FOXQI)
importin 11 (IPOII) +2.9481 Anabolic NDR NRE
importin 7 (IPO7) +4.7592 Anabolic NDR NRE
(200992at)
insulin-like growth +3.1870 Anabolic NDR NRE
factor 1
(somatomedin C)
(IGF1)
insulin-like growth -13.6898 Anabolic NDR NRE
factor binding protein
1 (IGFBPI)
insulin-like growth -18.5362 Anabolic NDR NRE
factor binding protein
5 (IGFBPS)
interleukin 1 family NDR NRE +4.1682 Catabolic
(IL1F8)
interleukin 17D -2.8729 Anabolic NDR NRE
(IL17D)
interleukin 32 (IL32) +2.8646 Anabolic NDR NRE
interleukin 33 (IL33) +48.2994 Anabolic +3.2614 Anabolic
interleukin 6 -3.7429 Anabolic NDR NRE
(interferon (IL6)
interleukin 8 (IL8) +3.0542 Anabolic +3.6065 Anabolic
laminin (LAMBI) +2.9398 Anabolic -2.9140 Catabolic
leptin (obesity -2.8863 Anabolic NDR NRE
homolog (LEP)
32
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TABLE 6-continued
Gene Family
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#1 Fold with
Increase/Decrease Osteoblast
for Fourth Time and bone
Varying cell
Stimulation Field Development
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#3 Fold with
Increase/Decrease Osteoblast
for Fifth Time and bone
Varying cell
Stimulation Field Development
matrix NDR NRE +2.8543 Catabolic
metallopeptidase 14
(membrane-inserted)
(MMP14)
mitogen-activated +3.6457 Anabolic NDR NRE
protein kinase
associated protein 1
(MAPKAPI)
mitogen-activated +8.9929 Anabolic NDR NRE
protein kinase-
activated protein
kinase 2/inhibition of
apoptosis, regulation
of cell development,
and cell differentiation
(MAPKAPK2)
rush homeobox 1 +3.4459 Anabolic NDR NRE
(MSXI)
Notch homolog 2 +5.1985 Anabolic +3.6551 Anabolic
(Drosophila)
(NOTCH2)
nuclear factor of +4.0922 Anabolic NDR NRE
activated T-cells
(NFATC3)
osteoglycin (OGN) +3.2508 Anabolic NDR NRE
pallidin homolog +2.9546 Anabolic NDR NRE
(mouse) (PLDN)
parathyroid hormone- —3.9816 Catabolic NDR NRE
like hormone
(PTHLH)
peroxisome +3.7661 Anabolic NDR NRE
proliferator-activated
receptor alpha
(PPARA)
platelet derived +11.8582 Anabolic +3.7643 Anabolic
growth factor C
(PDGFC)
procollagen-lysine +3.1194 Anabolic NDR NRE
(PLOD2)
procollagen-proline +3.1958 Anabolic +3.3121 Anabolic
(P4HB)
protocadherin beta 6 +3.5486 Anabolic NDR NRE
(PCDHB6)
protocadherin gamma +3.1857 Anabolic NDR NRE
subfamily A
(PCDHGA3)
reticulocalbin 1 —2.8536 Anabolic NDR NRE
(RCNI)
runt-related +4.2303 Anabolic NDR NRE
transcription factor 2
(RUNX2)
signal transducer and —4.7015 Anabolic +3.0161 Catabolic
activator of
transcription 1
(S TAT 1)
signal transducer and —3.1518 Anabolic NDR NRE
activator of
transcription 2
(S TAT 2)
signal transducer and +2.9537 Anabolic NDR NRE
activator of
transcription 3 (acute-
phase response
factor) (STAT3)
SMAD family member +2.9000 Anabolic NDR NRE
1 (SMADI)
M
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TABLE 6-continued
Gene Family
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#1 Fold with
Increase/Decrease Osteoblast
for Fourth Time and bone
Varying cell
Stimulation Field Development
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#3 Fold with
Increase/Decrease Osteoblast
for Fifth Time and bone
Varying cell
Stimulation Field Development
SMAD family member +2.9848 Anabolic NDR NRE
2 (SMAD2)
SMAD family member +4.8768 Anabolic +2.9077 Anabolic
4 (SMAD4)
SMAD family member +3.6075 Anabolic NDR NRE
6 (SMAD6)
spare/osteonectin +3.3007 Anabolic NDR NRE
(SPOCKI)
SRY (sex determining +6.0198 Anabolic NDR NRE
region Y)-box 4
(SOX4) (201417at)
SRY (sex determining +2.9461 Anabolic NDR NRE
region Y)-box 9
(campomelic
dysplasia (SOX9)
stanniocalcin 1 —133.3427 Anabolic NDR NRE
(STCI)
stanniocalcin 2 —6.3031 Anabolic —2.8380 Anabolic
(STC2)
superoxide dismutase +4.1182 Anabolic NDR NRE
2 (SOD2)
syndecan 1 (SDCI) +2.8761 Anabolic NDR NRE
TRAF family member- +2.9982 Anabolic NDR NRE
associated NFKB
activator (TANK)
tumor necrosis factor —5.8708 Anabolic NDR NRE
(ligand) superfamily
TRAIL (TNFSFIO)
tumor necrosis factor —3.9019 Anabolic +3.3676 Catabolic
(ligand) superfamily
(TNFSFI3B)
tumor necrosis factor —13.4107 Anabolic NDR NRE
(ligand) superfamily
(TNFSFIS)
tumor necrosis factor NDR NRE —2.9040 Anabolic
receptor superfamily
(TNFRSFIOD)
v-akt murine +4.3325 Anabolic NDR NRE
thymoma viral
oncogene homolog 3
(protein kinase B
(AKT3)
TABLE 7
Anabolic or Anabolic or
Catabolic Catabolic
Effect Effect Effect Effect
of Genes of Genes
Associated Associated
#2 Fold with #4 Fold with
Increase/Decrease Osteoblast Increase/Decrease Osteoblast
for Fourth Time and bone for Fifth Time and bone
Varying cell Varying cell
Gene Family Stimulation Field Development Stimulation Field Development
actin (ACT13)
ADAM
metallopeptidase
domain 10 (ADAM10)
ADAM
metallopeptidase
domain 17 (tumor
necrosis factor
(ADAM17)
NDR NRE
+3.8784 Anabolic
+3.0926 Anabolic
+3.2497 Anabolic
+3.1870 Anabolic
+3.1296 Anabolic
36
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TABLE 7-continued
Gene Family
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#2 Fold with
Increase/Decrease Osteoblast
for Fourth Time and bone
Varying cell
Stimulation Field Development
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#4 Fold with
Increase/Decrease Osteoblast
for Fifth Time and bone
Varying cell
Stimulation Field Development
ADAM -5.5601 Catabolic NDR NRE
metallopeptidase
domain 33 (ADAM33)
ADAM +4.3910 Anabolic NDR NRE
metallopeptidase with
thrombospondin type
1 motif (ADAMTS1)
ADAM -2.9113 Catabolic NDR NRE
metallopeptidase with
thrombospondin type
1 motif (ADAMTS6)
B-cell CLL/lymphoma +4.2264 Anabolic +2.9836 Anabolic
6 (zinc finger protein
51) (BCL6)
biglycan (BGN) +10.8190 Anabolic NDR NRE
bone gamma- +3.4068 Anabolic NDR NRE
carboxyglutamate
(gla) protein
(osteocalcin)
(BGLAP)
bone morphogenetic +265.1634 Anabolic NDR NRE
protein 2 (BMP2)
calcium/calmodulin- +4.2280 Anabolic NDR NRE
dependent protein
kinase (CaM kinase)
II delta (CAMK2D)
calmodulin 1 NDR NRE +2.9379 Anabolic
(phosphorylase
kinase (CALMI)
calumenin (CALU) +3.2043 Anabolic +3.1993 Anabolic
cartilage oligomeric +17.7007 Anabolic -4.0956 Catabolic
matrix protein
(COMP)
catenin (cadherin- +4.5090 Anabolic +3.5238 Anabolic
associated protein)
(CTNNB I )
cathepsin C (CTSC) -4.9355 Anabolic NDR NRE
cathepsin H (CTSH) -3.1342 Anabolic NDR NRE
cathepsin S (CTSS) -2.8325 Anabolic NDR NRE
chondroitin sulfate +3.2199 Anabolic NDR NRE
proteoglycan 4
(CSPG4)
clusterin (CLU) +26.2849 Anabolic NDR NRE
collagen (COL12A1) +3.6143 Anabolic +2.9117 Anabolic
collagen (COL16A1) -2.8512 Anabolic -3.0354 Anabolic
collagen (COL1A1) +2.8438 Anabolic NDR NRE
collagen (COL3A1) +5.4512 Anabolic NDR NRE
collagen (COL4A2) +3.0110 Anabolic NDR NRE
collagen (COL5A2) +2.9639 Anabolic NDR NRE
cytochrome P450 -2.9175 Anabolic NDR NRE
(CYP11A1)
cytochrome P450 -11.9176 Anabolic NDR NRE
(CYP19A1)
cytochrome P450 +7.1220 Anabolic +4.4823 Anabolic
(CYPIB1)
cytochrome P450 +5.3640 Anabolic NDR NRE
(CYP24A1)
cytochrome P450 -2.9432 Anabolic NDR NRE
(CYP4V2)
cytochrome P450 +4.7959 Anabolic NDR NRE
(CYP51A1)
cytochrome P450 -4.6752 Anabolic NDR NRE
(CYP7B1)
endoglin (Osler- +2.9055 Catabolic NDR NRE
Rendu-Weber
syndrome 1) (ENG)
Fas (TNF receptor +3.0606 Anabolic NDR NRE
superfamily (FAS)
fibrillin 1 (FBNI) +3.3971 Anabolic +3.6475 Anabolic
38
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TABLE 7-continued
Gene Family
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#2 Fold with
Increase/Decrease Osteoblast
for Fourth Time and bone
Varying cell
Stimulation Field Development
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#4 Fold with
Increase/Decrease Osteoblast
for Fifth Time and bone
Varying cell
Stimulation Field Development
fibroblast growth -2.9045 Anabolic NDR NRE
factor 1 (acidic)
(FGF1)
fibroblast growth +6.0853 Anabolic NDR NRE
factor 18 (FGF18)
embryonic
development
fibulin 1 (FBLNI) +4.8829 Anabolic NDR NRE
forkhead box Q1 +3.2639 Anabolic NDR NRE
(FOXQI)
importin 11 (IPOII) +3.5238 Anabolic NDR NRE
importin 7 (IPO7) +4.7773 Anabolic NDR NRE
insulin-like growth +2.9529 Anabolic NDR NRE
factor 1
(somatomedin C)
(IGF1)
insulin-like growth -11.3487 Anabolic NDR NRE
factor binding protein
1 (IGFBPI)
insulin-like growth -3.4126 Anabolic NDR NRE
factor binding protein
2 (IGFBP2)
interleukin 1 family NDR NRE +4.6908
(IL1F8)
interleukin 32 (IL32) +2.8329 Anabolic NDR NRE
interleukin 33 (IL33) +77.4903 Anabolic +3.4328 Anabolic
interleukin 4 induced -2.9266 Anabolic NDR NRE
1 (IL4I1)
interleukin 6 -4.0698 Anabolic NDR NRE
(interferon (IL6)
interleukin 8 (IL8) NDR NRE +4.4075 Anabolic
laminin (LAMBI) +3.5168 Anabolic NDR NRE
leptin (obesity -2.8432 Anabolic NDR NRE
homolog (LEP)
mitogen-activated +3.4504 Anabolic NDR NRE
protein kinase
associated protein 1
(MAPKAPI)
mitogen-activated +6.6319 Anabolic +3.4968 Anabolic
protein kinase-
activated protein
kinase 2
(MAPKAPK2)
rush homeobox 1 +3.1872 Anabolic NDR NRE
(MSXI)
Notch homolog 2 +6.6681 Anabolic +3.9031 Anabolic
(Drosophila)
(NOTCH2)
nuclear factor of +4.4679 Anabolic NDR NRE
activated T-cells
(NFATC3)
osteoglycin (OGN) +2.9048 NDR NRE
pallidin homolog +3.7839 NDR NRE
(mouse) (PLDN)
parathyroid hormone- -2.9471 Anabolic NDR NRE
like hormone
(PTHLH)
peroxisome +3.3980 Anabolic NDR NRE
proliferator-activated
receptor alpha
(PPARA)
platelet derived +8.6547 Anabolic NDR NRE
growth factor C
(PDGFC)
(222719sat)
platelet-derived +2.8343 Anabolic NDR NRE
growth factor alpha
polypeptide (PDGFA)
i t
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TABLE 7-continued
Gene Family
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#2 Fold with
Increase/Decrease Osteoblast
for Fourth Time and bone
Varying cell
Stimulation Field Development
Anabolic or
Catabolic
Effect Effect
of Genes
Associated
#4 Fold with
Increase/Decrease Osteoblast
for Fifth Time and bone
Varying cell
Stimulation Field Development
procollagen-lysine +3.2120 Anabolic NDR NRE
(PLOD2)
procollagen-proline +3.3854 Anabolic +3.2322 Anabolic
(P4HB)
protocadherin 7 +4.3290 Anabolic NDR NRE
(PCDH7)
protocadherin beta 15 +3.1245 Anabolic NDR NRE
(PCDHBIS)
protocadherin beta 5 +4.9055 Anabolic NDR NRE
(PCDHBS)
protocadherin gamma +3.6665 Anabolic +3.1682 Anabolic
subfamily A
(PCDHGAIO
PCDHGAII ///
PCDHGA12
PCDHGA3
PCDHGAS
PCDHGA6)
protocadherin gamma +3.2147 Anabolic NDR NRE
subfamily C
(PCDHGC3)
runt-related +4.6912 Anabolic NDR NRE
transcription factor 2
(RUNX2)
signal transducer and —5.6924 Anabolic +3.5656 Catabolic
activator of
transcription 1
(S TAT 1)
signal transducer and —3.1503 Anabolic +3.3033 Catabolic
activator of
transcription 2
(S TAT 2)
signal transducer and +2.8810 Anabolic +2.8416 Anabolic
activator of
transcription 3 (acute-
phase response
factor) (STAT3)
SMAD family member +2.9680 Anabolic NDR NRE
2 (SMAD2)
SMAD family member +4.4233 Anabolic +3.2649 Anabolic
4 (SMAD4)
SMAD family member +3.8208 Anabolic NDR NRE
6 (SMAD6)
SMAD family member +3.4806 Anabolic NDR NRE
7 (SMAD7)
spare/osteonectin +3.2869 Anabolic NDR NRE
(SPOCKI)
SRY (sex determining +3.6585 Anabolic NDR NRE
region Y)-box 4
(SOX4)
SRY (sex determining +2.8642 Anabolic NDR NRE
region Y)-box 9
(campomelic
dysplasia (SOX9)
stanniocalcin 1 —76.1478 Anabolic NDR NRE
(STCI)
stanniocalcin 2 —7.3838 Anabolic NDR NRE
(STC2)
superoxide dismutase +3.6248 Anabolic NDR NRE
2 (SOD2)
syndecan 1 (SDCI) +3.0232 Anabolic NDR NRE
TIMP NDR NRE +2.8771 Anabolic
metallopeptidase
inhibitor 3 (Sorsby
fundus dystrophy
(TIMP3)
tumor necrosis factor —3.1995 Anabolic NDR NRE
(ligand) superfamily
BAFF (TNFSFI3B)
EN
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TABLE 7-continued
Anabolic or Anabolic or
Catabolic Catabolic
Effect Effect Effect Effect
of Genes of Genes
Associated Associated
#2 Fold with #4 Fold with
Increase/Decrease Osteoblast Increase/Decrease Osteoblast
for Fourth Time and bone for Fifth Time and bone
Varying cell varying cell
Gene Family Stimulation Field Development Stimulation Field Development
tumor necrosis factor —3.2316 Anabolic +3.6523 Catabolic
(ligand) superfamily
TRAIL (TNFSFIO)
tumor necrosis factor +2.8649 Anabolic NDR NRE
receptor superfamily
(TNFRSFIOA)
tumor necrosis factor NDR NRE —2.9102 Anabolic
receptor superfamily
(TNFRSFIOD)
tumor necrosis factor —2.9260 Catabolic NDR NRE
receptor superfamily
(TNFRSFIIB)
tumor necrosis factor NDR NRE +3.4511 Catabolic
receptor superfamily
(TNFRSF21)
v-akt murine +4.0693 Anabolic NDR NRE
thymoma viral
oncogene homolog 3
(protein kinase B
(AKT3)
Based on consensus related art publications, it was antici-
pated that the results associated with the fourth and fifth
time-varying stimulation fields would be substantially or at
least reasonably equal given that the B-Field magnitudes
were substantially the same. However, the actual results
refuted this expectation. In fact, the actual results of the third
experiment indicate that the differences in gene expressions
were not substantially the result of B-Field magnitude.
Rather, other FOMs related to a field's profile affect cellular
activity wherein said other FOMs can overcome the strength
(or lack thereof) of a B-Field magnitude. Of the 47,000
genes analyzed, approximately 2500 genes responded to the
fourth time-varying stimulation field as compared to
approximately 450 genes responding to the fifth time-vary-
ing stimulation field which comprises a greater than 550%
increase in gene response. The difference in the number of
gene responses and associated percentage difference is
indicative of the fourth time-varying stimulation field having
a significantly greater effect on HOBS as compared to the
fifth time-varying stimulation field. Hence, as discussed, the
results refute the related art expectation that substantially or
at least reasonably similar results were expected due to
substantially similar B-Field magnitudes associated with the
fourth and fifth time-varying stimulation fields.
Certain types of genes and genomic cascades respond
differently to different stimulation fields of predetermined
profiles. And, in regard to the fourth time-varying stimula-
tion field, anabolic genes are substantially up-regulated as
compared to other types of genes. Further, the inventors
realized another unanticipated result in that the percentage
of regulated genes associated with the HOB sample exposed
to the fourth time-varying stimulation field was much higher
as compared to the percentage of regulated genes associated
with the HCH sample exposed to the second time-varying
stimulation field. Thus, the same stimulation field of prede-
termined profile affects genetic response in HCH differently
as compared to HOB. Thus, the same stimulation field
profile can be applied to different tissue wherein different
3o results occur. In regard to different genetic responses in
HCH and compared to HOB, the inventors postulate that due
to substantial differences in the total CA2+ and K+ density
in cartilage vs. mineralized bone, the subcellular transcrip-
tion signals are different when exposed to the same stimu-
35 lation field. This presents an unanticipated explanation for
the many different results seen in scientific articles using
PEMFs. Thus a variety of potential tuning solutions for
different mammalian tissues is likely.
Still further, the inventors realized that based on the fact
40 that different stimulation fields can affect cells with regard to
regulation of regenerative and reparative genes to produce a
net regenerative (i.e., anabolic) or net reparative (i.e., cata-
bolic) effect, different stimulation fields and their associated
exposure times or time schedules can be used in combina-
45 tion with each other to design customized therapeutic appli-
cations. Multiple embodiments exist for combining stimu-
lation fields and their associated exposure times or time
schedules. For example, in an embodiment, a stimulation
field (and its associated exposure times or time schedules)
50 tuned to produce a net catabolic effect in HOB cells, HCH
cells, or both can be initially used to stimulate a net catabolic
effect. After a predetermined amount of catabolic or repara-
tive effect(s) are realized, another stimulation field (and its
associated exposure times or time schedules) tuned to pro-
55 duce a net anabolic effect in HOB cells, HCH cells, or both
can be utilized until a predetermined amount of anabolic or
regenerative effect(s) are realized. The process can be
repeated if so desired. Alternatively, in another embodiment,
it is conceivable that a therapeutic application may be
60 customized to use a stimulation field (and its associated
exposure times or time schedules) tuned to produce a net
catabolic effect in HOB cells, HCH cells, or both in com-
bination and simultaneously with a stimulation field (and its
associated exposure times or time schedules) tuned to pro-
65 duce a net anabolic effect in HOB cells, HCH cells, or both.
Still further, the use of tuned stimulation fields in series, in
parallel, or both may be employed.
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These results represent a means to tune at least one
predetermined profile of a time-varying stimulation field to
preferentially stimulate (up-regulate, down-regulate, or a
combination of both) the biochemical cellular and sub-
cellular molecular responses to trigger the activation of 5
known mammalian genes responsible for the restoration,
repair, and maintenance of cartilage and bone. Specifically,
said preferential stimulation can be targeted to specific
genes, gene families, or a combination of both, responsible
for anabolic effects, catabolic effects, or a combination of io
both. Tables 2, 4, 6, and 7 are incorporated herein as
identifying examples of such specific genes and gene fami-
lies that may be targeted for preferential stimulation by a
tuned time-varying stimulation field of at least one tuned
predetermined profile. It has been demonstrated that the use 15
of cell samples (such as HOB or HCH, however any kind of
biological cell sample can be used depending on the bio-
logical matter of interest) and microcarriers encased in
RWVs in combination with a stimulation field generator can
be used in an empirical manner to tune a time-varying 20
stimulation field of at least one predetermined profile to
optimize genetic anabolic effects, catabolic effect, or a
combination of both. With particular reference to FIG. 9, for
example, as can be extracted by the sequence of experiments
previously described, a tuning step 50 may comprise pro- 25
viding at least one set of cellular samples in at least one
rotating wall vessel 51; exposing said at least one set of
cellular samples to at least one experimental time-varying
stimulation field comprising at least one experimental pre-
determined profile 52; conducting at least one gene expres- 30
sion analyses to said at least one set of cellular samples 53;
analyzing the genetic anabolic and catabolic effects from the
results of said at least one gene expression analyses 54;
generating at least one conclusion from said step of analyz-
ing 55; comparing said at least one conclusion with prede- 35
termined criteria 65; if said at least one conclusion does not
meet predetermined criteria, adjusting said at least one
experimental predetermined profile based on said at least
one conclusion 56; and selecting said at least one tuned
time-varying stimulation field profile for said predetermined 40
tuned exposure time or said plurality of tuned exposure time
sequences 57. The predetermined criteria in step 56 may
comprise, for example, a predetermined number of anabolic
genetic effects or responses; catabolic genetic effects or
responses; or a combination of both. With particular refer- 45
ence to FIG. 10, for example, the step of analyzing the
genetic anabolic and catabolic effects may be comprised of:
selecting a predetermined set of genes 58; calculating a fold
change for each gene in said set of genes from the results of
said at least one gene expression 59; determining if each of 50
said fold change is consistent with up-regulation or down-
regulation for said each gene 60; and classifying each of said
fold change as an anabolic or catabolic effect based on said
up-regulation or down-regulation for said each gene 61. The
said step of generating at least one conclusion may be 55
comprised of: establishing a relative value for each of said
anabolic or catabolic effect on said up-regulation or down-
regulation for said each gene 62; comparing each of said
relative value in combination 63; selecting a conclusion
comprised of either a substantive net anabolic effect, a 60
substantive net catabolic effect, a net anabolic effect, a net
catabolic effect, or no determinative effect 64.
One skilled in the art would readily appreciate that the
present innovation is well adapted to carry out the objects
and obtain the ends and advantages mentioned, as well as 65
those inherent therein. The present examples along with the
methods, procedures, treatments, and biological materials
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described herein are presently representative of embodi-
ments and preferred embodiments; are exemplary; and are
not intended as limitations to the scope of the innovation.
Changes therein and other uses will occur to those skilled in
the art which are encompassed within the spirit of the subject
innovation as defined by the scope of the claims.
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What is claimed is:
1. A method to up-regulate or down-regulate an expres-
sion level of human genes of interest, comprising the steps
of:
positioning a time-varying stimulation field generating
apparatus proximate to a sample of human chondrocyte
cells or human osteoblast cells or a combination
thereof; and
generating, via said apparatus, a time-varying stimulation
field with a B-Field magnitude of about 0.059 G or 0.65
G and a frequency of about 10 Hz for the human
chondrocyte cells or a B-Field magnitude of about 0.65
G and a frequency of about 10 Hz or 15 Hz for the
human osteoblast cells, a rising slew rate of about 2.0
kG/s to about 4.5 kG/s, a rise time, a falling slew rate
of about 4.5 kG/s to about 15.5 kG/s, a fall time, a
wavelength of about 500 ms, a duty cycle of about 80%
or 30%, and a sample exposure time of 720 hours
predetermined for upregulation or down-regulation of
the expression level of the human genes of interest in
the sample.
2. The method of claim 1, wherein said time-varying
stimulation field generating apparatus comprises:
a power source;
a control component operably connected to said power
source; and
a transmission component operably connected to said
control component and said power source.
3. The method of claim 1, wherein the mammalian genes
of interest for said human chondrocyte cells are a Wnt
signaling gene, forkhead box gene, a sex determining region
Y Sry-related high mobility group box gene, a parathyroid
hormone gene, a transforming growth factor beta super
gene, a latent transforming growth factor gene, an integrin
gene, a interleukin gene, a thrombospodin gene, a laminin
gene, a proteoglycan gene, a collagen gene, an insulin gene,
a disintegrin and metalloproteinase gene, an actin gene, a
catenin gene and a cadherin super gene.
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4. The method of claim 1, wherein the mammalian genes
of interest for said human osteoblast cells are a forkhead box
gene, a parathyroid hormone gene, an integrin gene, a
interleukin gene, a thrombospodin gene, a laminin gene, a
proteoglycan gene, an osteoglycin gene, a collagen gene, an
insulin gene, a disintegrin and metalloproteinase gene, a
disintegrin and metalloproteinase with thrombospondin
motifs gene, a matrix metallopeptidase gene, an actin gene,
a catenin gene, a cadherin super gene, a B-cell lymphoma
gene, a calmodulin calcium-modulated gene, a calumenin
gene, a cathepsin gene, a clusterin, cytochrome P 450 super
gene, an endoglin gene, a fibrillin gene, a fibroblast growth
factor gene, a leptin gene, a mitogen-activated protein kinase
activated protein kinase gene, a muscle segment homeobox
gene, a neurogenic locus notch homolog protein gene, a
peroxisome proliferator-activated receptors gene, a platelet
derived growth factor gene, a reticulocalbin gene, a runt
related transcription factors gene, a signal transducer and
activator of transcription gene, a similar to mothers against
decapentaplegic gene, a stanniocalcin gene, a superoxide
dismutase gene, a syndecan gene, a tumor necrosis factor
super gene, an AKT/protein kinase B signaling gene, and an
importin gene.
5. The method of claim 2, wherein said predetermined
time-varying stimulation field is in the form of a substan-
tially square, biphasic waveform.
6. The method of claim 1, wherein said rise time is
between about 125 µs to 1 ms.
7. The method of claim 1, wherein said fall time is
between about 125 µs to 1 ms.
8. The method of claim 1, further comprising the step of
contacting said human chondrocyte cells or human osteo-
blast cells with Vitamin D, Vitamin K or a combination of
Vitamin D and Vitamin K.
9. A method of activating mammalian human genes
associated with bone formation, comprising the steps of:
generating at least one time-varying stimulation field in
the form of a substantially square, biphasic waveform
by using a time-varying stimulation field generating
apparatus;
manipulating a B-Field magnitude, rising slew rate, rise
time, falling slew rate, fall time, frequency, wave-
length, duty cycle, sample exposure time or time
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sequences, or a combination thereof of the at least one
time varying stimulation field to values predetermined
for activating the mammalian genes;
exposing samples of mammalian cells associated with
5 bone formation to said at least one time varying stimu-
lation field manipulated for activation of the mamma-
lian genes; and
contacting said mammalian cells associated with bone
formation with Vitamin D, Vitamin K or a combination
10 of Vitamin D and Vitamin K at the exposing step.
10. The method of claim 9, wherein said time varying
stimulation field generating apparatus comprises:
a power source;
a control component operably connected to said power
15 source; and
a transmission component operably connected to said
control component and said power source.
11. The method of claim 9, wherein said mammalian
genes are bone morphogenetic protein family genes, actin
20 family genes, thrombospondin family genes, lamanin family
genes, proteoglycan family genes, collagen family genes,
tumor necrosis factor genes family, transforming growth
factor family genes, actin/cytoskeleton related family genes
or a combination thereof.
25 12. The method of claim 9, wherein said B-Field magni-
tude is between about 0.6 G to about 50 G.
13. The method of claim 9, wherein said B-Field fre-
quency is from about 10 Hz to about 16 Hz.
14. The method of claim 9, wherein said rise time is from
30 about 0.75 ms to about 1 ms and said rising slew rate is from
about 2.0 kG/s to about 4.5 kG/s.
15. The method of claim 9, wherein said fall time is from
about 125 µs to about 300 µs and said falling slew rate from
about 4.5 kG/s to about 15.5 kG/s.
35 16. The method of claim 9, wherein said duty cycle from
about 65% to about 80%.
17. The method of claim 9, wherein said B-field magni-
tude is about 0.65 G.
18. The method of claim 9, wherein said frequency is
40 about 10 Hz.
19. The method of claim 9, wherein said cellular samples
are damaged cartilage, bone or a combination thereof.
